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SUMMARY 
The activation of the protein kinase C (PKC) family of serine/threonine kinases contributes to 
the modulation of insulin signaling and the PKC-dependent phosphorylation of IRS-1 has 
been implicated in the development of insulin resistance. Here we demonstrate Ser-357 of rat 
IRS-1 as a novel PKC-δ-dependent phosphorylation site in skeletal muscle cells upon 
stimulation with insulin and phorbol ester using phospho-Ser-357 antibodies and active and 
kinase dead mutant of PKC-δ. Phosphorylation of this site was simulated using IRS-1 Glu357 
and shown to reduce insulin-induced tyrosine phosphorylation of IRS-1, to decrease activation 
of Akt and subsequently to diminish phosphorylation of GSK-3. When the phosphorylation 
was prevented by mutation of Ser-357 to alanine, these effects of insulin were enhanced. 
When the adjacent Ser-358, present in mouse and rat IRS-1, was mutated to alanine, which is 
homologous to the human sequence, the insulin-induced phosphorylation of GSK-3 or 
tyrosine phosphorylation of IRS-1 was not increased. Moreover, both, active PKC-δ and 
phosphorylation of Ser-357 were shown to be necessary for the attenuation of 
insulinstimulated Akt phosphorylation. The phosphorylation of Ser-357 could lead to 
increased association of PKC-δ to IRS-1 upon insulin stimulation, which was demonstrated 
with IRS-1 Glu357. Together, these data suggest that phosphorylation of Ser-357 mediates at 
least in part the adverse effects of PKC-δ activation on insulin action. 
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1- INTRODUCTION 
 
1.1 Diabetes 
 Diabetes mellitus (DM) is a metabolic disorder of multiple aetiologies characterized by 
chronic hyperglycaemia with disturbances of carbohydrate, fat, and protein metabolism 
resulting from defects of insulin secretion, insulin action, or a combination of both (1). The 
epidemic of type 2 diabetes mellitus (T2DM) and impaired glucose tolerance is one of the 
main causes of morbidity and mortality worldwide (2). In 2007, it is estimated that diabetes 
currently affects 246 million people worldwide and is expected to affect 380 million by 2025 
with the most of this increase occurring in developing countries. The Western Pacific region 
and the European region have the highest number of people with diabetes, approximately 67 
and 53 million respectively. The highest rate of diabetes prevalence is to be found in the North 
American region (9.2%) followed by the European region (8.4%) (3). 
 
1.2 Insulin resistance 
The pathogenesis of type 2 diabetes involves abnormalities in both, insulin action and 
secretion (4). At the molecular level, insulin resistance, the first detectable defect in type 2 
diabetes, correlates with impaired insulin signaling in peripheral tissues (5). Clinically, the 
term insulin resistance implies that higher than normal concentrations of insulin are required 
to maintain normoglycemia. On a cellular level, this term defines an inadequate strength of 
insulin signaling from the insulin receptor downstream to the final substrates of insulin action 
involved in multiple metabolic and mitogenic aspects of cellular function (6). The earliest 
abnormality observed in insulin resistance is a decrease in insulin-induced glucose uptake in 
skeletal muscle and adipose tissue and a reduced ability of the hormone to suppress glucose 
production by the liver (2;7). At the early stage of the pathology, pancreatic ß cells first 
compensate for peripheral insulin resistance by increasing insulin secretion to maintain 
euglycemia. When chronic, this hyperinsulinemia exacerbates insulin resistance and 
contribute to ß cell failure leading to the development of impaired glucose tolerance and overt 
clinical type 2 diabetes.  
 Insulin resistance is also associated with a variety of physiological and patho-physiological 
states other then type 2 diabetes, such as hypertension, glucose intolerance, and obesity (7) 
However, understanding the molecular mechanisms that modulate insulin signaling under 
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these conditions, has proved a more difficult ‘nut to crack’; even 50 years after the discovery 
of insulin, therefore a full understanding of insulin action is still evolving (8). 
 
1.3 Insulin signaling - the basics 
The discovery of insulin in 1921 was one of the key biological and medical advances of the 
twentieth century. However, it took the rest of the century to understand how this hormone 
regulates intracellular metabolism (8). The insulin signaling system plays a significant role in 
many physiological processes, including carbohydrate and fat metabolism, reproduction, 
cellular growth, and survival (9). Nonetheless, insulin is best known for its role in the 
regulation of blood glucose, as it suppresses hepatic gluconeogenesis and promotes glycogen 
synthesis and storage in liver and muscle, triglyceride synthesis in liver and storage in adipose 
tissue, and amino acid storage in muscle (10). Thus, understanding the cellular mechanisms of 
insulin action may contribute significantly to new treatments for type 2 diabetes mellitus, 
which grounds for a cohort of systemic disorders, such as dyslipidemia, hypertension, 
cardiovascular disease, stroke, blindness, kidney disease, female infertility, and neuro-
degeneration (11).  
 
1.3.1 Insulin receptor 
In the 1970s, the insulin receptor was discovered, and 10 years later the demonstration of its 
tyrosine kinase activity pointed toward the mechanism of signal transduction (12;13). A 150-
kb gene on chromosome 19 composed of 22 exons encodes the human pro-receptor. 
Dysregulation of insulin receptor gene splicing alters fetal growth patterns and contributes to 
insulin resistance in adults (14). The insulin receptor is the prototype for a family of 
homologous integral membrane proteins composed of two extracellular α-subunits and two 
transmembrane β-subunits that have protein tyrosine-kinase activity. There are at least seven 
tyrosine autophosporylation sites in three distinct regions of the β-subunits. The holoreceptor 
has a molecular weight of 350, 000 (15). The diverse biological actions of insulin and insulin-
like growth factor I (IGF-I) are initiated by binding of the polypeptides to their respective cell 
surface tyrosine kinase receptors. Insulin binding activates an intramolecular 
autophosphorylation reaction in which one β-subunit phosphorylates the other at several sites. 
This reaction activates the tyrosine kinase activity of the receptor enabling it to recruit and 
phosphorylate cellular substrates to initiate signal transduction (2;16). 
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1.3.2 Binding partners of insulin receptor 
Auto-phosphorylation of the A loop of β-subunit of IR creates binding sites for the other 
signaling proteins that modulate kinase activity including Grb10, Dock 1 and 2, Gab1 and 2, 
Cb1, APS  and SH2B (17). Auto-phosphorylation in the juxtamembrane region of IR is 
essential for the recruitment of IRS proteins that propagate insulin signal. 
Autophosphorylation in the COOH region of IR (Tyr1314 Tyr1328) is poorly understood, 
however, it has been shown to regulate tyrosine kinase activity and receptor internalization 
(18). The activated IR subsequently phosphorylate these adaptor proteins that function as 
docking sites for effector proteins containing Src homology-2 (SH2) domains (19). 
 
1.3.3 Insulin receptor substrates (IRS) 
The first evidence for such an adaptor protein emerged when insulin was shown to stimulate 
the tyrosine phosphorylation of a 185-kDa cytosolic protein (20), now known as insulin 
receptor substrate-1 (IRS1). Insulin receptor substrate (IRS) molecules are key mediators in 
insulin signaling and play a central role in maintaining basic cellular functions such as 
growth, survival, and metabolism (21). They act as docking proteins between the insulin 
receptor and a complex network of intracellular signaling molecules containing Src homology 
2 (SH2) domains. IRS proteins have no intrinsic catalytic activity but contain several domains 
that mediate interaction with the receptor and with IRS effectors.  
 
1.3.4 Structural organization of IRS proteins  
IRS proteins are composed of multiple interaction domains and phosphorylation motifs. An 
amino-terminal pleckstrin homology (PH) domain is adjacent to a phospho-tyrosine binding 
(PTB) domain. The nonconserved 46-residue linker between these two domains is disordered 
(22). The carboxy-terminal domain of IRS protein encodes numerous tyrosine and serine 
residues prone to phosphorylation (7;23). PH and PTB domain appear to facilitate recruitment 
of IRS proteins to activated insulin receptor. The PTB domain interacts with the tyrosine 
phosphorylated sequence NPXY in the insulin and insulin-like growth factor I (IGF-I) 
receptors. Deletion of both these domains in IRS-1 and IRS-2 almost completely prevent 
insulin stimulated tyrosine phosphorylation of the tail (24). No Src homology 2 or 3 (SH2 or 
SH3) domains have been identified in IRS proteins.  
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1.3.5 IRS isoforms 
Four members (IRS-1, IRS-2, IRS-3, IRS-4) of IRS family have been identified that differ as 
to tissue distribution, subcellular localization, developmental expression, binding to the 
insulin receptor and interaction with SH2 domain containing proteins. Nevertheless, the IRS-
protein isoforms display several structural similarities. Of note, mammalian IRS-1, -2, -3, -4 
and drosophila ortholog Chico contain a NH2-terminal pleckstrin homology (PH) domain 
adjacent to a PTB domain. The structures of these domains are remarkably similar (25). 
Despite the structural similarities between these IRSs, analyses of the IRS knockout mice 
demonstrated that IRS proteins have different functions in development and metabolism 
(26;27). Moreover, analysis of the human genome sequence reveals at least two putative IRS 
proteins, IRS-5 and IRS-6 (7). 
 
1.3.5.1 Insulin receptor substrate 1 (IRS- 1) 
IRS-1 was the first substrate of insulin receptor, identified in hepatoma cells using an 
antiphosphotyrosine antibody and was subsequently identified in several tissues, including 
muscle, heart, liver, adipocyte and kidney (20;28). Discovery of IRS-1 provided the first clue 
that substrate phosphorylation together with autophosphorylation are important steps in signal 
transduction. The human IRS-1 gene is localized on chromosome 2q36–37 (29). The 
relevance of IRS-1 in insulin/IGF-I signaling was primarily suggested by in vitro studies in 
which IRS-1 was overexpressed or its levels were decreased by anti-sense ribozyme, which 
resulted in increase in insulin sensitivity and responsiveness for glucose transport and 
enhanced mitogenetic effects of insulin (30;31). IRS1 controls body growth and peripheral 
insulin action (32). Mice lacking IRS-1 are small and insulin resistant, but generally fail to 
develop diabetes owing to consistent compensatory hyperinsulinemia (26). Islets from 
knockout mice lacking IRS-1 exhibited marked defects in insulin content and the insulin 
secretory response to glucose (33). In agreement with these results, it has been shown in 
human adipocytes that IRS-1 is the main docking protein for the binding and activation of PI 
3-kinase in response to insulin.  Defects in IRS expression and function have been reported in 
target tissues of insulin action from insulin resistant subjects. In skeletal muscle strips from 
morbidly obese subjects, it was observed a significant reduction in IRS-1 content, insulin-
stimulated IRS-1 phosphorylation, and PI 3-kinase activation that was paralleled by a 
decrease in insulin-stimulated glucose uptake (34). 
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Taken together, these data indicate that IRS-1 plays a key role in mediating both metabolic 
and mitogenic effects of insulin in peripheral tissues such as muscle and adipose tissue, and 
suggest a novel important role for IRS-1 in β cell function. Thus, insulin receptor substrate 1 
is one of the  important early site of divergence in insulin signaling, which seems to be a 
relevant target for modulation of the signal (35). 
 
1.3.5.2 Insulin receptor substrate 2 (IRS-2) 
IRS-2 was cloned from a myeloid cell line and was identified as the alternative IR substrate in 
liver and muscle of IRS1-null mice (36;37). The amino acid sequence identity between IRS-1 
and IRS-2 is 43%, with some domains such as the PH and PTB domains exhibiting higher 
degrees of identity (65 and 75%, respectively) (38-40). Mice lacking IRS-2 develop diabetes 
with in 6-10 weeks of age owing to peripheral insulin resistance and ß-cell failure (26). 
Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes (41). 
IRS-2 regulates brain growth, body weight control, glucose homeostasis, and female fertility 
(42). It is clear that IRS1 and IRS2 are responsible for relaying insulin signals from the 
receptor to intracellular effectors, but, IRS1 and IRS2 differ significantly from each other 
(43). For example, it has been shown that IRS-1 and IRS-2 differ in their sub-cellular 
localization, IRS-2 is dephosphorylated more rapidly and activates PI3-kinase more 
transiently than IRS-1, thus indicating that differences in kinetics of activation may contribute 
to the diversity of the insulin signaling transduced by IRS-1 and IRS-2 (44). In fact, IRS-1 
appears to have its major role in skeletal muscle whereas IRS-2 appears to regulate hepatic 
insulin action as well as pancreatic β cell development and survival (21). 
 
1.3.5.3 Insulin receptor substrate 3 (IRS- 3) 
Rodents express IRS-3 which is largely restricted to adipose tissue where it display activity 
similar to IRS-1 (27), whereas the gene might not be active in humans (45) . Although 
disruption of IRS-3 has small effect, mice with combined deficiency of IRS-1 and IRS-3 
developed sever lipoautrophy associated with hyperglycemia, hyperinsulinemia and insulin 
resistance (27). In addition to metabolic signals, IRS-3 seems to be able to mediate mitogenic 
signals (46). 
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1.3.5.4 Insulin receptor substrate 4 (IRS- 4) 
IRS-4 expression is limited to thymus, brain, kidney and ß-cell (47). Overall, IRS-4 displays 
only 27% and 29% sequence identity with IRS-1 and IRS-2, respectively. In vitro studies with 
HEK cells confirmed that IRS-4 binds PI3-kinase and Grb-2 (48). Overexpression of IRS-4 in 
rat adipocytes led to a marked increase in the number of GLUT4 molecules recruited to the 
cell surface (27). More recently, it has been shown that IRS-3 and IRS-4 may act as negative 
regulators of IGF-I signaling by suppressing the function of IRS-1 and IRS-2 at several steps 
(46). 
 
1.3.5.5 Insulin receptor substrate 5 and 6 (IRS- 5, - 6) 
IRS-5/DOK4 and IRS-6/DOK5 were recognized in the human genome owing to their NH- 
terminal tendum PH-PTB domain (49) however, they contain very short COOH tails with a 
few tyrosine phosphorylation sites, so their function remains unknown (7). 
 
1.3.6 Binding partners of IRS-1 
The tyrosine phosphorylation sites in the COOH-terminal of each IRS protein recruit and 
regulate various downstream signaling proteins. Over 20 tyrosine phosphorylation residues 
contribute to docking sites for downstream signaling proteins. However, only a few sites that 
bind p85, Grb2, or SHP2 have been formally identified (50). Many of the tyrosine residues 
cluster in the common motifs that recruit or activate enzymes (PI3-Kinase, SHP2, fyn) or 
adaptor molecules (Grb2, nck, crk, SH2B). Grb2 and possibly SHP2 couple Grb2/SOS to IRS 
proteins, which promotes ras       raf cascade (51). All IRS proteins contain multiple p85 
binding motifs that recruit the PI3-Kinase, which is the best studied insulin signaling pathway.  
 
1.3.7 The PI3-Kinase cascade 
PI3-kinase is ubiquitous and used by nearly all receptor signaling systems to promote cell 
division survival and growth. During insulin and IGF signaling, the PI3-kinase is accessed 
through tyrosine phosphorylation of IRS- proteins (17). IRS proteins couple insulin/IGF 
receptors to the PI3-kinase and extra cellular signal-regulated kinase (ERK) cascade. Other 
signal transduction proteins interact with IRS including Grb2, an adaptor protein that contains 
SH3 domains, which in turn associates with the guanine nucleotide exchange factor son-of  
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 Fig. 1. IRS protein-dependent insulin/IGF-I-signaling cascade and various biological 
effects. 
Activation of the receptors for insulin and IGF-I results in tyrosine phosphorylation of the IRS 
proteins. The IRS proteins thereby bind PI3-kinase, Grb2/son of sevenless (SOS). The 
Grb2/SOS complex mediates the activation of p21ras, thereby activating the ras/raf/mitogen-
activated protein (MAP) kinase (MEK)/MAP kinase cascade. The activation of PI 3-kinase by 
IRS protein recruitment results in the generation of PI-3,4-diphosphate(PI3,4P2) and PI-
3,4,5-triphosphate (PI3,4,5P3). In aggregate, PI3,4P2 and PI3,4,5P3 activate a variety of 
downstream signaling kinases, including PKB. PKB regulates glycogen synthase kinase 3 
(GSK-3), which may regulate glycogen synthesis, and a variety of regulators of cell survival. 
PKB-mediated phosphorylation of the proapoptotic protein BAD inhibits apoptosis. The IRS 
proteins also interact with a variety of signaling molecules containing Src homology 2(SH2) 
domains, to regulate lipid and protein metabolism and cell growth. 
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MAPK  “mitogen activated protein kinase”  mTor  “mammaliam target of rapamycin”  
PKC  Protein kinase C  PKB/Akt  Protein kinase B  
GSK3 Glycogen synthase kinase-3 IR Insulin receptor 
IGF-R Insulin like Growth Factor receptor Ras/raf A membrane associated GTPases 
/MAP kinase kinase kinase 
  
 
sevenless (sos) and elicits activation of the MAPK cascade leading to mitogenic responses 
(52) (Fig. 1). Activation of the PI 3-kinase cascade is an important insulin/IGF-regulated 
pathway. PI3-kinase is a dimer composed of a 110-kDa catalytic subunit that is associated 
non-covalently to a 55- or 85-kDa regulatory subunit. PI3-kinase is activated when the 
phosphorylated YMXM motifs in IRS proteins occupy both src homology-2 (Sh2) domains in 
the regulatory subunit (53). Products of PI3-kinase, including phosphatidylinositol-3,4-
bisphosphate and phosphatidylinositol-3, 4, 5-trisphosphate, attract serine kinases to the 
plasma membrane, including the phosphoinositide-dependent kinase (PDK1 and PDK2) and 
at least three protein kinase B (PKB) isoforms (Fig. 1). During co-localization at the plasma 
membrane, PDK1 phosphorylates and activates PKB-1, -2, or -3. 
 
 
1.3.8 Insulin-activated AKT/PKB  
Kinase Akt is one of the best characterized insulin-stimulated enzyme as it is broadly 
implicated in growth and metabolism (54;55). The activated protein kinase B (PKB or Akt) 
phosphorylates many substrates to control various biological signaling cascades, including 
glucose transport, protein synthesis, glycogen synthesis, cell proliferation, and cell survival, in 
various cells and tissues (Fig. 1)(37;56). AKT/protein kinase B (PKB) phosphorylates 
glycogen synthase kinase-3α (GSK3α) and GSK3β at serine residues located in Arg–Xaa–
Arg–Xaa–Xaa–Ser/Thr motifs (where Xaa is any amino acid) (57). This motif is crucial for 
the specificity of AKT/PKB (8). There is also increasing evidence that phosphorylation of the 
Rab GTPase-activating protein AS160 by AKT/PKB underlies the insulin-stimulated 
translocation of the glucose transporter GLUT4 to the plasma membranes of muscle cells and 
adipocytes, a crucial event in promoting the uptake of glucose from the blood (58). 
 
1.3.9 Insulin-activated GSK-3 
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase that consists of highly 
homologous α and β isoforms (59), phosphorylates and thereby inactivates glycogen synthase 
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(GS), resulting in reduced glycogenesis (57;60). Indeed, overexpression of GSK3 β in skeletal 
muscle of male mice is associated with a marked decrease in glucose tolerance (61). An 
association between skeletal muscle GSK3 and insulin resistance has been demonstrated in 
type 2 diabetes and animal models of insulin resistance (62;63). Additionally by inhibiting 
GSK-3, insulin stimulates the dephosphorylation and activation of eIF2B, contributing to an 
increased rate of protein synthesis (64). 
 
1.4 Regulatory aspects of insulin signaling: cause of type 2 diabetes  
 
1.4.1 Genetic aspects 
Polymorphisms have been identified in human genes encoding proximal insulin signaling 
components that might contribute to metabolic disease. Although insulin receptor 
polymorphism provides important insight into receptor function they fail to uncover a general 
cause of type 2 diabetes (65). A few polymorphisms in the gene of IRS-1 have been found, 
some of which are more common in type 2 diabetic patients (66), of these, the Gly to Arg 
change at codon 972 (Arg972 IRS-1) is the most common, and has been studied most 
extensively (67;68). However, they don’t reveal a simple genetic basis for insulin resistance 
(67). Thus genetic defects in the insulin signaling system validate the importance of the 
insulin signaling cascade, but they fail to explain the common cause of type2 diabetes. 
 
1.4.2 Tyrosine phosphorylation of IRS-1 proteins 
The COOH-terminal end of each IRS protein contains a set of tyrosine phosphorylation sites 
that act as on/off switches to recruit and regulate various downstream signaling proteins (7). 
Tyrosine phosphorylation of IRS-1 proteins constitutes the first event beyond activation of the 
IR tyrosine kinase that unleashes the intracellular transmission of insulin signals (69). 
Therefore,  phosphorylation of IRS1 on tyrosine residues is mandatory for insulin-stimulated 
responses (70). The IRS proteins are phosphorylated on tyrosine residues by the activated 
insulin receptor kinase (71). It results in the generation of binding sites for SH2 domain 
containing proteins. Many of the tyrosine residues cluster into common motifs that bind and 
possibly activate specific effector proteins, including enzymes, the phosphotyrosine 
phosphatases and the Src-like kinase or adapter molecules (72). At the molecular level, 
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decrease in glucose uptake is linked to a reduced tyrosine phosphorylation of IRS1 in animal 
models of insulin resistance and  in type 2 diabetic patients (21).  
While the mechanisms involved in the decrease in IRS1 tyrosine phosphorylation have not 
been completely identified, the involvement of serine phosphorylation of IRS1 (70), protein 
phosphatases (2) and polymorphism in IRS gene (73) has been pointed out over the last 
decade. 
1.4.3 Serine phosphorylation of IRS-1: Modulator of insulin signaling 
 In addition to tyrosine phosphorylation, both the insulin receptor and IRS proteins undergo 
serine phosphorylation, which may attenuate signaling by several mechanisms (74). IRS-1 
and IRS2 each contain more than 100 potential serine phosphorylation sites. Current studies 
have demonstrated hyper-serine phosphorylation of IRS-1 on Ser-302, Ser-307, Ser-612, and 
Ser-632 in several insulin-resistant rodent models (75;76), as well as in lean insulin-resistant 
offspring of type 2 diabetic parents (77). Lately a study provide evidence for inhibitory role of 
serine phosphorylation of IRS-2 in hepatic insulin signaling by indicating phosphorylation of 
serines 484/488 of IRS-2 by JNK and GSK-3 (78). While the phosphorylation of IRS1 on 
tyrosine residue is required for insulin-stimulated responses, the phosphorylation of IRS1 on 
serine residues has a dual role, either to enhance or to terminate the insulin effects (70). 
 
1.4.3.1 Serine phosphorylation as a feedback regulatory mechanism of 
insulin signaling 
Control mechanisms are essential for cellular signaling. Tyrosine phosphorylated IRS proteins 
are key players in propagating insulin signaling and are the targets of such feedback 
regulatory systems. Regulation of IRS proteins involves proteasome-mediated degradation 
(79), phosphatase mediated dephosphorylation, (80) or Ser/Thr phosphorylation. The latter is 
an attractive regulatory mechanism because it enables multilevel control of the activation of 
IRS kinases and the specific targets among potential Ser/Thr phosphorylation sites in IRS 
proteins that might play regulatory roles during the insulin response (Figure 1). Ser/Thr 
phosphorylation reduces IRS-1 ability to undergo Tyr phosphorylation by the insulin receptor 
kinase and might serve as a physiological negative feedback control mechanism to turn off 
insulin signaling by uncoupling the IRS proteins from their upstream and downstream 
effectors (Fig. 2) (81-83).  
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1.4.3.2 Serine phosphorylation of IRS proteins as a negative modulator of 
insulin signaling 
Recent studies reveal that agents that induce insulin resistance, exploit phosphorylation-based 
negative feedback control mechanisms otherwise utilized by insulin itself to uncouple the 
insulin receptor from its downstream effectors and thereby terminate insulin signal  
Fig .2. Serine phosphorylation of IRS-1 as modulator of insulin action and resistance. 
Ser/Thr phosphorylation of IRS proteins has a dual role, either to enhance or to terminate 
signaling by insulin. Ser residues of the phosphotyrosin -binding (PTB) domain of IRS-1, 
located within consensus protein kinase B (PKB) phosphorylation sites, presumably function 
as positive effectors of insulin sigailing, thus, generating a positive-feedback loop for insulin 
action. Insulin also activates mTOR and PKC, which mediate phosphorylation of Ser/Thr 
residues within the IRS protein either directly or through activation of downstream effectors 
such as IκB kinase β (IKKβ). Phosphorylation of these sites is part of the negative-feedback 
control mechanism induced by insulin that results in the termination of insulin signaling. 
Agents that abrogate insulin action, such as free fatty acids (FFA) and tumor necrosis factor 
α (TNFα), take advantage of this negative feedback control mechanism by activating Ser/Thr 
kinases (e.g. JNK, PKCs, IKKβ, mTOR, MAPK) that, by mediating phosphorylation of IRS 
proteins, inhibit the function of IRS proteins, terminate insulin action and induce insulin 
resistance (84). 
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transduction (Fig. 2) (85). The involvement of serine phosphorylation of IRS1 in the 
desensitization of insulin action has been pointed out over the last decade (21). Considerable 
data suggest that various pathological conditions associated with insulin resistance can 
promote serine phosphorylation of IRS-1 proteins. Stress-induced cytokine like TNF-α cause 
insulin resistance, at least in part, by serine phosphorylation of IRS-1. Regarding insulin 
resistance, studies have also suggested that agents, such as free fatty acids (FFA) (86;87), 
cellular stress (70), amino acids (88;89), endothelin-1 (90-92), angiotensin II (93) and 
hyperinsulinemia (94) which induce insulin resistance, can also activate serine/threonine 
kinases that phosphorylate IRS1 and inhibit its function (Fig. 2). The plasma concentrations of 
FFA (86), amino acids , angiotensin II (95;96), and endothelin-1 (97;98) are elevated in 
insulin resistant, obese and type 2 diabetic patients (99). IRS-1 Ser-312 and Ser-636  
phosphorylation increased, in the insulin-resistant offspring of parents with type 2 diabetes 
compared to the control subjects (77). Many Ser/Thr kinases phosphorylate IRS-1 including 
Raf, MEK, MAPK, P90rsk, JNK and PKC isoforms. Kinases downstream of the PI3-kinase 
cascade, PDK1, AKT, mTOR, p70S6K, and GSK-3β are also involved (100-103). 
Consequently, the inhibition of IRS1 functions could represent a unifying mechanistic link 
between all factors involved in insulin resistance. 
 
1.4.3.3 Mechanisms employed by Ser phosphorylation of IRS-1 to inhibit its 
function 
Several mechanisms have been proposed to explain how serine phosphorylation can regulate 
insulin signaling. Ser-307 phosphorylation inhibit PTB domain  function, which uncouple 
IRS-1 from insulin receptor (81). Some serine residues in IRS-1 bind 14-3-3 isoforms, which 
can target IRS-1 to sub-cellular compartments (Fig. 2) (104). Others sites might 
electrostatically block access to nearby tyrosine phosphorylation sites. Serine phosphorylation 
of IRS1 could induce conformational changes, steric hindrance, and cellular re-localization 
leading to decrease in tyrosine phosphorylation by IR, to reduce the recruitment of PI 3-kinase 
and to stimulate the IRS1 degradation pathway. Altogether, these events inhibit the IRS1 
functions and promote insulin resistance (70). 
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1.4.3.4 Serine phosphorylation as a positive modulator of insulin signaling 
The activation of PKB in response to insulin propagates insulin signaling and promotes the 
phosphorylation of IRS1 on serine residue in turn generating a positive-feedback loop for 
insulin action. Phosphorylation of Ser residues within the P-Tyr-binding (PTB) domain of 
IRS-1, by insulin-stimulated PKB, protects IRS proteins from the rapid action of PTPs, and 
enables the IRS proteins to maintain their Tyr-phosphorylated active conformation (105). 
Furthermore, activation of mTOR signaling induces Ser-302 phosphorylation and this 
positively influence signaling through the IR/IRS-1 axis (106). 
 
1.4.3.5 Important serine phosphorylation sites of IRS-1 
IRS-1 contains 232 Ser/Thr residues (23) many of which could be subjected to 
phosphorylation. Several candidate Ser residues were identified as potential targets for IRS-1 
kinases. These include Ser-24 (107), 302 (108), 307 (109), 318 (110), 332 (103), 408 (83), 
522 (111), 612 (91), 636 and 639 (112), 731 and 789 (113) ( Numbering of Ser residues of 
IRS-1 is based on the rat sequence) (Fig. 3). It is becoming apparent that Ser/Thr 
phosphorylation of IRS proteins has a dual function, serving either a positive or a negative 
modulatory role in insulin signaling. Under pathological condition, inducers of insulin 
resistance presumably trigger the phosphorylation of only the negative sites with no effects on 
the positive sites, thus preventing the propagation of insulin signals mediated by IRS proteins 
and thus causing insulin resistance (114). Furthermore, data describing one specific serine 
residue of IRS-1 either as a positive (106;115) or as a negative (116;117) regulatory 
phosphorylation site suggest a time-and-stimulus dependent function of serine 
phosphorylation of IRS-1 (110). 
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Fig. 3. Schematic diagram of rat IRS-1 serine  phosphorylation sites. 
Amino acid residues from 1 to 1235 are indicated. The N-terminal PH and PTB domains of 
IRS-1 are represented as boxes. IRS-1 serine phosphorylation sites with their relative location 
in IRS-1 are indicated. Positive, negative or dual role of the sites in insulin signaling is 
represented in different colours.  
 
1.5 Protein kinase C as modulators of insulin signal transduction 
Among IRS-1 kinases, members of the protein kinase C family of serine/threonine kinases 
have received considerable attention for their regulatory role in insulin signaling. The protein 
kinase C (PKC) family plays important roles in many intracellular signaling events, cell 
growth and differentiation (118;119). It is composed of a number of individual isoforms 
which belong to three distinct categories, conventional, novel and atypical, based upon their 
structurally distinct N-terminal regulatory domains. The major insulin-responsive tissues, 
skeletal muscle, liver and adipose tissue, express PKC isoforms from each of the categories, 
and the total number in each of these cells is in the range of 6–8 isoforms. These include 
conventional PKCs; α, βI and βII, novel PKCs; δ, ε and θ, and atypical PKCs; ζ or λ. Each of 
these isoforms has been shown to be activated by insulin stimulation or conditions important 
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for effective insulin stimulation (120;121). Most PKC isoforms have a dual action in 
stimulating insulin signaling and feeding back to induce insulin resistance in disease (122). 
 
1.5.1 PKCs mediated upregulation of insulin signaling  
There is increasing evidence that protein kinase C (PKC) isoforms modulate insulin-signaling 
pathways in both, positive and negative ways. Insulin stimulation or conditions important for 
effective insulin stimulation, activates PKCs α, βII, δ and ε in several cell types. In cultured 
mayotubes and intact muscles, it was shown that PKC βII is required for insulin-stimulated 
glucose uptake (123;124). Although PKC δ is primarily being reported as negative modulator 
of insulin signaling. But some of the reports suggest its positive effects on insulin signaling as 
well. Sampson et al (125) showed that insulin specifically induces PKC δ to associate with IR 
and that this IR-PKC δ association plays an important role in early IR signaling. In another 
study it was reported that insulin-induced GLUT4 translocation and glucose uptake was 
abrogated by inhibition of PKC δ, either pharmacologically or by overexpression of a kinase 
dead (dominant negative) PKC δ. Moreover, overexpression of WT PKC δ in the primary 
skeletal muscle cells increased GLUT4 translocation and glucose uptake in the absence of 
insulin stimulation (126).  
 A potential role of PKC ε as a transducer of insulin action was shown by its overexpression 
in NIH-3T3 fibroblasts, where the translocation of GLUT1 transporters to plasma membrane 
was greatly enhanced compared to (untransfected) cells where no translocation of GLUT1 
was detected (127).The expression of PKC ε was shown to be depressed in muscle from 
Zucker obese insulin resistant rats (128). In one of the study it was reported that 4 weeks of 
physical exercise improved insulin-signaling responses in these animals and that this was 
associated with an increase in association of PKC ε with IR (145).  
 
1.5.2 PKCs mediated downregulation of insulin signaling  
While the activation of PKC isoforms is not necessarily a negative regulation of insulin action 
(85;129;130). But PKCs have been implicated in impaired insulin signaling for over one 
decade (131-133), including classical PKC, novel (134) and more recently also atypical PKC 
isoforms (135). Knockout of PKC-α in mice enhances insulin signaling and PKC-θ-deficient 
mice are protected from fat-induced insulin resistance (136;137). Protein kinase C α, β and ζ 
are increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus 
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(138). It would thus appear that the previously described positive regulation by PKC δ of IR 
signaling might involve the intervention of another protein such as Src tyrosine kinase 
(Sampson 60). PKCα, expressed in cells co-expressing either IR or IRS1 (3T3ir, HEK293, 
COSIR) induced their phosphorylation, supporting the idea that PKCα might in fact play a 
role in development of insulin-resistance (134;139). As a modulator of insulin action, PKCε 
(140) has been shown to increase the inhibitory effect of TNF-α on insulin signaling (141). In 
skeletal muscle from obese, insulin resistant patients, the decrease in PKC θ expression was 
noted (142). In summary, each of PKC isoforms has been shown one way or another to 
modify insulin-stimulated effects in one or all of the insulin-responsive tissues (143).  
 
1.5.2.1 Regulation of serine phosphorylation of IRS-1 by PKC isoforms 
In vitro and in vitro studies have shown that increased Ser/Thr phosphorylation of IRS-1 by 
protein kinase C (PKC) impairs insulin signaling (144). PKCs phosphorylates IRS proteins on 
serine residues and acts as a negative feedback control regulator that turns off insulin signals 
by inducing the dissociation of IRS proteins from IR (81). Indeed, 12-O-tetradecanoylphorbol 
13-acetate, a potent activator of various PKC isoforms, effectively inhibits both, IRS-1 
interactions with the juxta-membrane region of the insulin receptor and insulin’s ability to 
phosphorylate IRS proteins, thus implicating diacylglycerol-activated PKCs as potential 
regulators of IR-IRS interactions (81). Prolonged insulin stimulation of PKC-ζ can also 
participate in the negative regulation of insulin signaling by phosphorylating IRS-1 at serine 
residues (145). The phosphorylation of Ser-318 of IRS-1 by PKC-ζ  has been suggested to be 
involved in the negative regulation of insulin signal transduction (81;110;146). Additionally, 
PKC-θ-dependent phosphorylation of Ser-1101 of  IRS-1 has been reported  in muscle cells 
(147). 
 
1.5.2.2 PKC-δ-mediated downregulation of insulin signaling via serine 
phosphorylation of IRS-1 
As a serine–threonine kinase, PKC-δ might be expected to function primarily as a negative 
regulator of IR signaling, particularly in view of the role of serine phosphorylation on 
activities of IR and IRS (148-150). In deed many studies have shown that PKC-δ decrease 
tyrosine phosphorylation of IRS-1 and may be involved in  increase in serine phosphorylation 
of IR and IRS-1 (122;151), suggesting that the same kinases that mediate insulin signaling 
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might also play roles in negative feedback of it. PKC-δ, although presumably requiring co-
expression of IRS-1, inhibits the tyrosine kinase activity of the insulin receptor in human 
kidney embryonic cells (152) . In addition, PKC-δ has been overexpressed in CHO cells and 
when activated by phorbol esters found to increase serine phosphorylation of IRS-1 
(153;154). In the same report, it was shown in H4IIE hepatoma cells that expression of either 
constitutively active PKC-δ, or of wild type PKC-δ followed by phorbol ester stimulation, 
inhibited tyrosine phosphorylation of IRS-1 in response to insulin. Previously, PKC-δ was 
shown to phosphorylate several serine residues, including Ser-307, Ser-323 and Ser-574 
(human sequence) that inhibit IRS-1 tyrosine phosphorylation (155). It has been suggested 
that the phosphorylation of IRS-1 on serine/threonine residues is the mechanism by which 
PKCs regulate insulin action (122). A few PKC-δ-dependent phosphorylation sites had been 
identified in recent times, among them, Ser-24 (155), Ser-318 (155) are important. These 
results support the notion that insulin-activated PKC-δ serves as a negative regulator of IR 
signaling. 
 
 
1.6 Aims of the study 
Albeit Ser/Thr phosphorylation has been increasingly recognized as a negative counterbalance 
to positive IRS signaling through tyrosine phosphorylation (84) and  Ser/Thr phosphorylation 
could be a generalized mechanism for insulin resistance. But from a molecular perspective it 
has been difficult, however, to identify discrete sites that are both phosphorylated in vivo and 
when phosphorylated, have relevant functional consequences. Therefore attempts to reveal 
potential Serine phosphorylation sites in IRS-1 that regulate IRS-1 function during insulin 
simulation is worthwhile. Studies on regulation and function of novel serine phosphorylation 
sites of IRS-1 provide the rational mechanism to explain insulin resistance. 
With this background, following aims were established for the project to study the role and 
function of Ser-357 of IRS-1 in insulin signal transduction; 
 
1. To generate polyclonal phospho-site-specific Ser-357 antibody by immunizing the 
rabbits with synthetic peptide flanking phosphorylated-Ser-357. 
2. To purify the antiserum raised against phospho-Ser-357. Additionally, to eliminate 
cross reactivity of the antibody with adjacent Ser-358 by immuno-purification. 
3. To characterize specificity of phospho-site-specific Ser-357 in living cell. 
4. To study the stimuli which induce phosphorylation of Ser-357 in skeletal muscle. 
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5. To generate following mutants of IRS-1 by PCR site-directed mutagenesis, to study 
the function of Ser-357. 
 
a. Loss of function mutants 
i. IRS-1 Ala-357 
ii. IRS-1 Ala-357358 
b. Gain of function mutants 
i. IRS-1 Glu-357 
c. To study the single effect of Ser-357 and Ser-358  
i. IRS-1 Ala-358 
ii. IRS-1 Glu-357 Ala-358  
6. To study specific kinase involve in the phosphorylation of Ser-357. 
7. To study the function/biological relevance of Ser-357 phosphorylation in insulin 
signaling by investigation of effect of Ser-357 phosphorylation on following key 
molecules of insulin signaling; 
a. Tyrosine phosphorylation of IRS-1 
b. PKB/AKT phosphorylation 
c. GSK-3 phosphorylation 
8. To study the single function of Ser-357 and Ser-358 in insulin signaling 
9. To study the phosphorylation of Ser-357 in tissues from mice stimulated with insulin. 
10. To study the phosphorylation of Ser-357 phosphorylation in human mayotubes. 
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2- MATERIALS, SOFTWARE AND DEVICES 
2.1 Enzymes, Proteins, Nucleic acids and substrates 
λ- Protein phosphatase (λ-PPase)                      New England BioLabs, Beverly MA, USA 
λ-PPase reaction buffer                                    New England BioLabs, Beverly MA, USA 
Ligase                                                                 Roche molecular Diagnostics, Mannheim, 
Germany 
Ligase buffer                                                      Roche molecular Diagnostics, Mannheim, 
Germany 
Plasmid DNA IRS-1 (rat)                                  Lab Internal tool 
Plasmid DNA PKC-δ (mouse)                           Lab Internal tool 
Plasmid PKC ζ, PKC-θ, PKC-λ                       Lab Internal tool 
pcDNA3                                                             Lab Internal tool 
Plasmid DNA kinase-negative (KN) PKC-δ     Lab Internal tool 
Sequencing primers                                           Invitrogen, Karlsruhe, Germany 
PWO polymerase                                               peqLab GmbH, Munich, Germany 
10x Reaction buffer for Pwo polymerase  peqLab GmbH, Munich, Germany 
DNTPs peqLab GmbH, Munich, Germany 
Restriction endonuclease                                   Roche, Mannheim, Germany 
DNA-sequencing mix premix                           Perkin Elmer, Überlingen, Germany 
BamHI                                                               Roche Mannheim, Germany 
XhoI                                                                   Roche Mannheim, Germany 
 
2.2 Antibodies 
2.2.1 Antibodies against IRS-1 
IRS-1, polyclonal, against C-terminus              Dr Rainer Lehmann 
IRS-1, polyclonal, against C-terminus              Upstate, Lake Placid, USA 
IRS1 phospho-Ser 318, polyclonal                    Dr Rainer Lehmann 
 
2.2.2 Antibodies against PKCs 
Anti PKC δ, monoclonal                                   BD TransductionLaboratories, San Diego,  
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2.2.3 Antibodies against signal transduction molecules 
Anti-phospho-PKB/Akt (Ser 473)                     Cell Signaling, Frankfurt, Germany 
Anti-PKB/Akt (mouse), polyclonal                  Upstate Ltd, Wolverton, UK 
Anti-phospho-GSK-3α/β (Ser 21/9),                  
polyclonal  
Cell Signaling, Heidelberg, Germany 
Anti-GSK-3β (mouse) monoclonal                   Santa Cruz Biotechnology, USA 
Phospho-tyrosine, (P-tyr-100) (Mouse),            
monoclonal          
Cell Signaling, Frankfurt, Germany 
 
2.2.4 Secondary Antibodies 
Anti rabbit IgG HRP, goat Santa Cruz Biotechnology, USA 
Anti mouse IgG HRP, goat     Santa Cruz Biotechnology, USA 
 
 
2.3 Kits 
QIAquick Gel Extraction Kit                            Qiagen, Hilden, Germany 
Plasmid Maxi Kit (25)                                       Qiagen, Hilden, Germany 
Plasmid Mini Kit (25)                                       Qiagen, Hilden, Germany 
PCR Purification Kit (250)                                Qiagen, Hilden, Germany 
Quick change site-directed                               
mutagenesis kit 
Stratagene, Germany 
Bio-Rad-Kit                                                       Biorad, München, Germany 
 
2.4 Chemicals and solvents 
Agarose, peqGold                                               peqLab GmbH, Munich,Germany 
Ammonium persulfate (APS)                             Sigma, Steinheim, Germany 
β-Mercaptoethanol                                              Merck, Darmstadt, Germany 
BSA, bovine serum albumin                              Roche, Mannheim, Germany 
Bromophenol Blue                                              Merck, Darmstadt, Germany 
CaCl2                                                                   Sigma, Deisenhofen, Germany 
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Chloroform                                                         Merck, Darmstadt, Germany 
Dithiothreitol (DTT)                                          Sigma, Deisenhofen, Germany 
DMSO (dimethyl sulfoxide)                                 Merck, Darmstadt, Germany 
Dulbeccos-PBS                                                   Bio Whittaker, Verviers, Belgium 
EDTA                                                                 Sigma, Deisenhofen, Germany  
EGTA                                                                 Sigma, Deisenhofen, Germany  
Acetic acid                                                          Merck, Darmstadt, Germany 
Ethanol                                                                Merck, Darmstadt, Germany 
Ethidiumbromide                                                  Sigma, Deisenhofen, Germany 
Formaldehyde                                                       Aldrich, Steinheim, Germany 
FUGENE 6                                                         Roche, Mannheim, Germany 
Gelatine                                                               Merck, Darmstadt, Germany 
Glycine                                                                 Bio-Rad, Munich, Germany 
Glycerol                                                              Merck, Darmstadt, Germany 
HEPES   Sigma, Deisenhofen, Germany 
Insulin from bovine pancrease                           Sigma, Deisenhofen, Germany 
Isopropanol                                                         Merck, Darmstadt, Germany 
Rapid fixer for curix 60G354                              Agfa, USA 
Developer for curix 60A/BG153                         Agfa, USA 
Luminol (3-aminophtalhydrazide)                       Aldrich, Steinheim, Germany 
MgCl2 .6 H2O                                                      Sigma, Deisenhofen, Germany 
Sodium carbonate                                                Merck, Darmstadt, Germany 
Methanol                                                              Merck, Darmstadt, Germany 
Sodium chloride                                                   Merck, Darmstadt, Germany 
Sodium fluoride                                                     Merck, Darmstadt, Germany 
Natriumorthovanadate                                          Sigma, Deisenhofen, Germany 
Natriumpyrophosphate                                          Sigma, Deisenhofen, Germany 
p-Iodophenol                                                         Aldrich, Steinheim, Germany 
Ponceau                                                                Sigma, Deisenhofen, Germany 
Phorbol-12-myristate-13-acetate, for cell culture                      Sigma, Deisenhofen, Germany 
Protein A-Sepharose (Suspension)                     Amersham Biosciences, Freiburg, 
Germany 
Hydrochloric acid (37 %)                                    Applichem, Darmstadt, Germany 
SDS ultra pure                                                     Roth, Karlsruhe, Germany 
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Tetramethylethylenediamine (TEMED)                Roth, Karlsruhe, Germany 
Tris-(hydroxymethyl)-aminomethan                   Merck, Darmstadt, Germany 
Tris-(hydroxymethyl) aminomethan, ultrapur -                           ICN Biomedicals Inc, USA 
TritonX-100 (t-octylphenoxypolyethoxyethanol)                              Sigma, Deisenhofen, Germany 
Tryptan blue                                                       Biochrom, Berlin, Germany 
Hydrogen peroxide, 30% solution                      Aldrich, Steinheim, Germany 
Xylenecyanol                                                       Sigma, Deisenhofen, Germany 
 
 
2.5 Molecular markers 
“Low Molecular Weight” Marker                      Amersham Biosciences, Freiburg, 
Germany 
“High Molecular Weight” Marker                     Amersham Biosciences, Freiburg, 
Germany 
DNA-Molecular Weight Marker X (0.07-12.2 
kbp)                   
Roche Molecular Diagnostics, Mannheim, 
Germany 
 
 
2.6 Solutions and buffers 
All buffer substances and solvents were p.a. or better quality. Water was either Milli Q or 
HPLC-Water. 
  
Electrophoresis-running buffer: The Stock Buffer (10X) was prepared by dissolving 0.025 
M (30.3 g) Tris, 0.19 M (144 g) glycine, 0.1% (10g) SDS in 1 litrer of water, pH was adjusted 
at 8.3.  
Shortly before use stock was diluted by 1:10 with water to make 1X buffer. 
 
Separation gel buffer: 1.5 M (90.8 g) Tris, 2 % (10 g) SDS were dissolved in 500 ml H2O 
and pH was adjusted at 8.8.  
  
 
Stacking gel buffer: 0.5 M (30.3 g) Tris; 2 % (2 g) SDS were dissolved in 500 ml H2O. The 
pH was maintained with 25 % HCl at 6.8. 
 
  26 
Sample buffer, Laemmli: Stock buffer (5X) was prepared by dissolving 1M Tris HCl (pH 
6.8), 10% SDS; 1% bromphenolblue, 50% glycerol and β-mercaptoethanol, volume was 
raised to 10 ml with H2O. Stock was diluted by 1:5 with protein sample. 
 
Sample buffer, for agarose gel electrophoresis: 0.1 % bromphenolblue and 0.1% 
xylenecyanol, 60 % glycerol and 2 ml of 10x TAE buffer was dissolved in H2O and volume 
was raised till 10 ml. 
 
TAE(1X) (Tris/Acetat/EDTA): To prepare TAE buffer 40 mM Tris and 2 mM EDTA were 
dissolved in 1 liter of H2O.The  pH was adjusted with natrium acetate at 8.0. 
 
KCM buffer: Stock solution (5X) of KCM buffer was prepared by dissolving 0.5M KCl, 
0.25M MgCl2 and 0.09M CaCl2 in 1 liter of H2O.  
 
Blotting buffer: Stock blotting buffer (10X) was prepared by dissolving 480 mM Tris, 390 
mM glycin and 0.4 % SDS. 
100 ml of Stock blotting buffer was diluted with 200 ml Methanol and 700 ml H2O. 
 
10 x NET “G“:  Stock solution of NET “G“  was prepared by dissolving 1.5 M NaCl, 50 mM 
EDTA, 500 mM Tris, 10% Triton X100 and  2.5 % gelatin. Shortly before use the stock 
solution was diluted by 1:10 with water and pH was adjusted at 7.4 with HCl.    
 
ECL Solutions:  
Luminol : 0.5 M Luminol was prepared by dissolving 0.885 g of Luminol in 10 ml of 
DMSO. 
p-Iodophenol : 0.5M p-iodophenol was prepared by dissolving 1.1 g of p-iodophenol in 10 
ml of DMSO. 
Luminol and p-iodophenol solutions were stored away from light, at 4 ° C, and shortly before 
preparing ECL-Solution A and B, were liquified at room temperature (RT). 
 
0.1 M Tris/HCl buffer; 12.11 g Tris was dissolved in H2O and after adjusting the pH at 9.35 
volume was raised to 1 L. 
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ECL-Solution A; 880 µl, 0.5 mol   Luminol and 864 µl, 0.5 mol p-iodophenol were 
dissolved in 100 ml of 0.1 M Tris.  
ECL-Solution B; 0.0075 % (25ul from 30%)of H2O2  was dissolved in 100 ml of 0.1 M 
Tris/HCl: 25 µl 
The ECL-solutions A and B were stored at 4°C (maximum till 2 weeks) and were used in 1:1 
ratio. 
 
Stripping-buffer: Stripping buffer was prepared by dissolving 66 mM Tris, 0.5 % β-
Mercaptoethanol and 2 % SDS in 500 ml H2O, the pH was adjusted with around 10 ml, 25 % 
HCl at 6.8 and volume was raised with H2O to 1 liter. 
 
TBS/T buffer 10X :  The stock(10X) buffer was prepared by dissolving 200 mM Tris and 
1.37 M NaCl in 1 liter H2O. 
TBS/T buffer was prepared by dissolving TBS (10X) in water at 1:10 ratio and 0.1% Tween 
20 was added.in the end  addition of 5% BSA produced complete TBST/T buffer. 
 
BBS: To prepare BBS buffer for transfection in mammalian cells, 50 mM BES, 280 mM 
NaCl-solution and 1.5 mM Na2HPO4 solution was mixed and volume was raised till 90 ml 
with H2O. Then pH was adjusted exactly at 6.96 with NaOH and volume was raised till 100 
ml with H2O. 
BBS was sterilized by passing through a 0.22 micron filter. 
BBS buffer was first tested for a transfection test before use in the experiment. 
 
Lysis buffer (A):                                                             
Lysis buffer (A) was prepared by dissolving 50mM HEPES, 150mM NaCl, 1.5mM MgCl2, 
EGTA,  10% glycerole ,1% Triton-X-100, 100mM NaF and 10mM  Na4P2O7                                
together and the volume was raised with H2O to100ml. The pH was adjusted with 37% HCl to 
7.5. 
 Phosphatase inhibitor was freshly added to the lysis buffer shortly before use. 
 
Lysis buffer (B): Lysis buffer (B) was prepared by dissolving  50 mM Tris,150 mM NaCl 
and 1 % Triton X-100 together and the volume was raised with H2O to100ml. The pH was 
adjusted with 37% HCl to 7.6. 
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Phosphatase inhibitor (10 x): Stock solution (10X) of phosphatase inhibitor was prepared 
by dissolving 100 mM sodiumfluoride (NaF), 100 mM sodiumorthovanadate (Na3VO4), 100 
mM β-glycerophosphate (glycerol-2-phosphate) (C3H7O6PNa2) and 50 mM sodium 
pyrophosphate (Na4P2O7 .10 H2O) in water and volume was raised to 100ml. 
Solution was stored at -20°C in 1ml aliquots. 
 
 25 X solution of complete protease inhibitor: 
One tablet complete protease inhibitor (Roche Germany) was dissolved in 2 ml H2O to make 
a working solution of protease inhibitor. Protease inhibitor and phosphatase inhibitor were 
freshly added to the lysis buffer (B) shortly before use. 
 
HNTG-Buffer: HNTG buffer was prepared by dissolving 20 mM HEPES, 10 mM NaF, 150 
mM NaCl, 1% TritonX 100 and 10% Glycerol in 100ml H2Oand the pH was adjusted at 7.5. 
 
 
2.7 Culture media and antibiotics 
Glucose                                                               Sigma, Deisenhofen, Germany 
L-Glutamine                                                        GIBCO, Invitrogen, Karlsruhe, Germany 
Penicillin-streptomycin (PenStrep,                    
100.000 U) 
GIBCO, Invitrogen, Karlsruhe, Germany 
LB Broth,                                                            Miller Sigma, Deisenhofen, Germany 
LB Agar (Lennox L Agar)                                  Sigma, Deisenhofen, Germany 
DMEM 1 g Glc/L, without glutamine                Bio Whittaker, Verviers, Belgium 
DMEM 4.5 g Glc/L, without glutamine                         Bio Whittaker, Verviers, Belgium 
Ampicillin GIBCO,                                            Invitrogen, Karlsruhe, Germany 
 
LB-Medium (Luria-Broth): 25 g LB was dissolved in 1 L H2O and autoclaved. 
 
LB/Amp-Medium: after autoclaving ampicilin was added in 100 µg/ml concentration in the 
LB-Medium.  
LB/Amp-agar plates: after autoclaving and cooling the LB agar to 50°C, ampicillin was added 
in 100 µg/ml end concentration.15 ml LB-agar was added in each plate. 
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Standard medium for C2C12 and BHK-IR cells: Standard growth medium for cells was 
prepared  by mixing  430 ml of DMEM with 4.5 g glucose/L (Bio Whittaker, Verviers, 
Belgium), 10%  heat inactivated FCS, 100 U Penicillin and streptomycin, 2 mM glutamine, 
1mM sodium pyruvate and 1x non-essential amino acids.    
                       
Starvation medium for C2C12 and BHK-IR cells: Standard starvation medium for cells 
was prepared by mixing 500 ml of DMEM with 1 g glucose/L (Bio Whittaker, Verviers, 
Belgium) and 2 mM glutamine. 
 
2.8 Consumable material 
Gel blotting paper                                                Schleicher & Schüll, Dassel, Germany 
Hyper cassette for the detection of                       
chemiluminescence of protein blots 
Amersham Biosciences, Freiburg, Germany 
 
Hyperfilm ECL 18 x 24 cm2                                               Amersham Biosciences, Freiburg, Germany 
Millipore Filter 0.22 µm pore size                        Millipore, Bedford, USA 
Pipette tipps                                                         Eppendorf, Hamburg, Germany 
Nitrocellulose membrane protein                         
(BA 85 0.45µm)   
Schleicher Schüll, Dassel, Germany 
 
 
2.9 Cells and Bacterial strains 
 
2.9.1 Cells 
BHK (ATCC No. CCL 10): This cell line was established in 1961 from the kidney of five  
hamsters (Mesocricetus auratus), which was one day old. This cell line was kindly provided 
by R. Lammers, Tübingen.  
BHKIR-cell line is a cell line derived from BHK-cells with a stably transfected insulin 
receptor (IR). This cell line was kindly provided by NP Møller, Novo Nordisk, Denmark. 
 
C2C12: C2C12 cells were from ATCC (Wesel, Germany). 
 
 
2.9.2 Bacterial Strains 
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Competent E. coli- XL1 Blue                             
for  transformation      
 Novagen, Madison, USA                  
 
 
2.10 Laboratory equipments 
Genesys 5 spectrophotometer                             Spectronic, Runcorn, Cheshire, England 
Sterling Diagnostic Imaging apparatus               DuPont de Nemours, Bad Homburg, 
Germany 
HP Scanjet 4600                                                  HP, USA 
Hera safe hood                                               Heraeus , Germany 
Incubators                                                            Heraeus, Germany 
Thermocycler:                                                       
• Progene Techne, Dexford-Cambridge, UK 
• Mastercycler 5330 Eppendorf, Hamburg, Germany 
 Thermomixer comfort Eppendorf, Hamburg, Germany 
Vortex-Genie 2                                                    Scientific Industries, USA 
Heating block Scientific Industries, USA 
Water bath                                                       Julabo, Seelbach, Germany 
Centrifuges:  
• Minicentrifuge                                                     Qualtron Inc., Korea 
• AvantiTM J-25 with Rotors                                 Beckman, Munich, Germany 
      JA-17and JLA-10.500                               
• Biofuge fresco                                                      Heraeus/Kendro, Hanau, Germany 
• Megafuge 2.0 R                                                     Heraeus/Kendro, Hanau, Germany 
pH-Electrode SenTix 81                                       WTW, Weilheim, Germany 
pH-Meter inoLab                                                  WTW, Weilheim, Germany 
Electrophoresis chamber for agarose                   PolyMehr, Kassel, Germany 
Electrophoresis chamber for SDS-PAGE             PolyMehr, Kassel, Germany 
(20x20cm2)  
Blotting apparatus                                                PolyMehr, kassel, Germany 
Autoklav SANOclav                                             Wolf, Geislingen, Germany 
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2.11 Software 
GelScan 5.02 BioSciTec,                                    Frankfurt am Main, Germany 
Powerpoint 2000                                                 Microsoft Corporation, USA 
Reference Manager 10.0 ISI                               ResearchSoft, USA 
Literature –data base                                           http://www.ncbi.nlm.nih 
                                                                             gov/entrez/query.fcgi 
Protein data base                                                 http://www.expasy.org/ 
                                                                             http://www.expasy.org/prosite/ 
                                                                             http://www.hprd.org 
                                                                             /PhosphoMotif_finder   
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3. METHODS 
 
3.1 Protein Biochemical Methods 
 
3.3.1 SDS- polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate cell lysates and immunoprecipitated proteins, the discontinuous sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used (156). SDS binds to 
hydrophobic domains of proteins and disrupts their folded structure allowing them to exist 
stable in solution. The resulting SDS-protein complex is proportional to the molecular weight 
of the protein. SDS-protein complexes have all a negative charge and can be size-separated; 
SDS-treatment masks individual charge differences of proteins. During separation, SDS-
protein complexes are attracted to the anode and separated by enforcement through the porous 
acrylamide gel. Usually, proteins are first concentrated on a stacking gel and later separated 
on a separating gel.  
In this work, a separating gel of 7.5% acrylamide was used. Protein samples were combined 
with 5x Laemmli-buffer and heated at 95 °C for 5 min. 
 
3.3.2 Dephosphorylation assay  
For dephosphorylation of phosphorylated proteins from crude extract of cells, Lambda 
Proteins Phosphatase (λ-PPase) was used in dephosphorylation assays. λ-PPase is a Mn2+ -
dependent protein phosphatase with activity towards phosphorylated serine, threonine and 
tyrosine residues (157). Immunoprecipitated IRS-1 was incubated with 100 U of λ-
phosphatase and reaction buffer for 30 min at 30°C. Protein was then separated by SDS-
PAGE and analysed for dephosphorylation by western blot. 
 
 3.3.3 Quantification of proteins 
Total protein concentrations were determined using the dye-based Bradford assay. This assay 
is also referred to as Bio-Rad assay after the company which sells the kit. Aliquots of samples 
(ranging from 1-5 µl) were diluted in water. 800 µl of sample and 200 µl of the Bio-Rad-Kit 
were added. Extinction of the contained Coomassie Brilliant Blue G-250 dye, in response to 
various concentrations of protein, was then measured after 20-30 min at 595 nm in a 
spectrophotometer.  
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A standard curve with samples of known protein concentration was prepared in parallel, to 
assess the unknown protein concentrations. Bovine serum albumin, BSA, was used as a 
standard and the following dilutions were usually used for the standard curve: 
 
                Table 1. Known protein concentrations used for the standard curve. 
Standard Protein /µg µl BSA(200µg/ml) 
1 0 0 
2 4 20 
3 8 40 
4 12 60 
5 16 80 
6 20 100 
 
                  
Extinction was measured in plastic cuvettes and linear regression was used for the calculation 
of unknown protein concentration of the sample. 
 
3.2 Immunological Methods 
 
3.2.1 Generation and purification of phospho-site-specific-Ser-357 IRS-1 (p-Ser-357) 
antibodies  
 
The antibody was generated as described in (158). Polyclonal phospho-site-specific-Ser357 
antiserum was raised against a synthetic peptide (AHRHRGpSSRLHPPLNHSRSI) flanking 
Ser357 in IRS-1 (the numbering of IRS-1 refers to the rat sequence). The peptide was 
synthesized as a single peptide and as a multiple antigen peptide (MAP) 
(AHRHRGpSSRLHPPLNHSRSI)8 -(Lys)4-(Lys)2-Lys-Gly-OH using standard Fmoc/tBu 
chemistry as described above. After purification, the peptide was coupled to keyhole limpet 
hemocycanin using the glutardialdehyde method. The antiserum was obtained after repeated 
immunization of a rabbit with a 1:1 mixture of the peptide-keyhole limpet hemocycanin 
conjugate and the MAP. This antiserum was purified by multiple purification steps using 
immuno-affinity chromatography. In the first step of purification, the antiserum was purified 
using a non-phospho-peptide affinity column to eliminate the ability of the antibody to react 
with non-phosphorylated versions of the peptide. Since antiserum was showing cross 
reactivity with adjacent Ser358 as well, consequently, this cross reactivity was removed by 
performing an additional purification step, using phosho-Ser358 peptide, through immuno-
affinity chromatography. 
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3.2.2 Enzyme-linked immunoSorbent assay (ELISA) 
The wells of the microtiter plates (Nunc Brand Products, MaxiSorb surface, Wiesbaden, 
Germany) were coated with 5 µg of different peptides, listed in Table 1, in PBS in a final 
volume of 100 µl/well at 4°C overnight. The plates were washed three times with 200 µl of 
washing buffer (PBS/0.05% Tween 20, pH 7.0) and blocked with blocking buffer (PBS/0.05% 
Tween 20, pH 7.0, containing 2% BSA) for 2 hr at 37°C. After washing, the plates were 
treated for 1 h at 37°C with purified phospho-site-specific-Ser357 antibody (diluted in 
PBS/0.05% Tween 20, pH 7.0, containing 0.5% BSA) or the phospho-site-specific-Ser357 
antiserum. After washing, the plates were incubated with HRP-conjugated goat anti-rabbit Ig 
(Dianova, Hamburg, Germany; 1:5000 diluted in PBS/0.05% Tween 20/0.5% BSA). ABTS 
(azinodiethyl-benzthiazoline-sulfonate) and H2O2 in substrate buffer (citrate buffer 100mM, 
pH 4.5) was added (100 µl/well)  and the colour development analyzed at a wavelength of 405 
nm (158). 
 
3.2.3 Immunoprecipitation (IP) 
For co-immunoprecipitation, cells were lysed in lysis buffer-1, supplemented with 
phosphatase inhibitors. Immunoprecipitation was carried out by incubating 250 µg of protein 
with 3 µl of specific antibody and 30 µl of protein A-Sepharose to capture the complexes at 
4°C for 4 hours. Immunoprecipitates were washed twice with HNTG buffer supplemented 
with phosphatase inhibitors. After washing, protein was mixed with Laemmli (5X) and 
incubated at 95°C for 5 min. Sample was run on SDS-PAGE for Western blot analysis. 
 
3.2.4 Protein transfer to nitrocellulose membranes (Western blot) 
Western Blotting has been devised for the electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets and their subsequent detection by antibodies 
(159). This technique can give information about the size of protein (with comparison to a 
size marker or ladder in kDa), or identify the phosphorylation expression level.  
The separated protein of cellular extracts or IP from SDS-PAGE were transferred and 
immobilized to nitrocellulose membranes (0.45 µm pore size) by semi-dry Western blotting. 
Gel and membrane was placed between two blotting papers soaked in blotting buffer, to 
remove electrophoresis salts and detergents. Transfer was performed at 0.8 mA / cm2 for 2 
hours at room temperature.  
 
3.2.5 Staining of proteins on nitrocellulose membranes with Ponceau S  
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The transfer efficiency of proteins from polyacrylamide gel to nitrocellulose membrane was 
checked by Ponceau staining of the nitrocellulose membranes. It is a ready–to–use, reversible 
staining solution designed for rapid (5 minute) staining of protein bands on nitrocellulose 
membranes. Ponceau S stain is easily reversed with water washes, facilitating subsequent 
immunological detection. 
 
3.2.6 Detection of proteins by antibodies 
In a western blot, it is important to block the non-reacted sites on the membrane to reduce the 
amount of non-specific binding of proteins during subsequent steps in the assay. Therefore, 
nitrocellulose membranes were subsequently soaked with blocking agent (NET-G) in a plastic 
container. This step was repeated 3x, each time for 15 min. 
 
After the membrane was blocked, so that primary antibodies can not bind to the membrane 
non-specifically, a solution of the primary antibody or also called first antibody in NET-G 
was added and gently rocked for 2h at room temperature or overnight at 4 °C. Antibody 
solutions for Western blotting were typically diluted from 1/500 to 1/10,000. 
 
Membranes were subsequently washed in NET-G 4x, each time for 15 min (first antibody 
wash). Second antibodies were HRP-conjugate, anti-mouse or anti-rabbit, depending on the 
animal in which the primary antibody was raised (the host species). A dilution (ranging from 
1:2500 -1:5000) of the appropriate second antibody was added and incubated at room 
temperature for 30-60 min. The second antibody recognizes the Fc portion of the first 
antibody. Second antibody wash was performed four times, lasting 15 min, each.   
 
Enhanced chemiluminescence system was used for the detection of proteins of interest on 
nitrocellulose membranes. This method has become the method of choice for Western blot 
analysis because it gives several advantages over other detection methods.The membranes 
were incubated with a 1:1 (v/v) ratio of solution A and B (as described in materials) for 3 min. 
Emitted light was detected by hyperfilm ECL films. Films were developed using a Sterling 
Diagnostic Imaging apparatus  
 
3.2.7 Densitometry 
Protein images on films were scanned using a HP Scanjet (4600 Series). Densitometry was 
carried out using Gelscan professional V5.1 software. 
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3.2.8 Stripping antibodies from nitrocellulose- membranes 
Stripping is the term used to describe the removal of primary and secondary antibodies from 
the membrane. Stripping was used when more than one protein was investigated on the same 
blot or the same protein with different antibodies (for example when a phospho-specific 
antibody was probed, then the relative total amount of protein was reprobed). 
 The detection reagents from membrane was removed and membrane was washed for 15 min 
in NET”G”. The blot was incubated with stripping buffer at 56°C for exactly 30 min in a 
water bath. The membrane was blocked with NET”G” for another 15 min and incubated with 
a new antibody solution overnight.  
Membranes were stored after use in heat-sealed plastic bags at 4 °C.  
 
3.3 Molecular methods 
 
3.3.1 Cell cultivation 
All works were carried out under sterile conditions in a "Sterile Hood". 
Cryopreserved cells C2C12/BHK-IR were transferred in 15 ml DMEM (4.5g/L glucose) 
standard growth medium for C2C12/BHK-IR cells. Cells were incubated at 37 °C / 5% CO2 
either in 15 cm plates or 175 cm2 cell culture flasks. After 4 hours, the medium was changed 
and after 24 hours cells were sub-cultivated in 1:10 split ratio. 
 
3.3.2 Cell splitting/passaging  
C2C12 cells were grown for 48 hours and BHK-IR for 72 hours. As they were 80% confluent, 
they were considered ready for splitting. For splitting, first medium was removed, and then 
cells were rinsed with 5 ml of PBS. After removal of PBS, 4 ml trypsin-EDTA was added in 
the plate and incubated at 37 °C / 5% CO2 for 4 min. When cells were detached from the plate 
5 ml DMEM growth media was added to stop trypsin activity and cells were centrifuged at 
900 rpm for 4 min. The pellet was resuspended in 1ml DMEM growth media. 100 µl of cell 
suspension (1:10 split ratio) was added in a new plate containing 15 ml fresh DMEM growth 
media. Cells were incubated in 37 °C / 5% CO2 for another 48 hours. 
 
3.3.3 Cell counting 
For cell culture experiments it is necessary to determine cell concentration to use particular 
number of cells in the experiment.  
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50µl of cell suspension was mixed with 450 µl of Trypan blue. After short vortexing, 20 µl of 
this mixture was added in the Neubauer cell counting chamber. Cells were counted in four 
large corner squares. The cell number was determined by multiplying the average of four 
squares with 105 (104 chamber factor x dilution factor).  
 
3.3.4 Transfection 
Transfection is the introduction of cloned eukaryotic DNA into cultured mammalian cells. 
The most widely used method is transfection mediated by calcium phosphate, although the 
mechanism remains ambiguous, it is believed that the transfected DNA enters the cytoplasm 
of the cell by endocytosis and it is transferred to the nucleus. To transfer wild type or mutated 
IRS-1 into the cells, pRK5 was used as a vector. For transient transfection, cells were seeded 
one day before and grown to 80% confluence in 6 well plates having 1x105 cells per well in 2 
ml DMEM growth medium. All transfections were performed with standard calcium 
phosphate precipitate protocol (160). In this method,  cells were transfected with 4µg of rat 
IRS-1 cDNA in pRK5-vector or PKCs cDNA in  pLXSN (161;162). Total DNA amount used 
for transfecting one well of 6 well plate was 4 µg, while performing co-transfection of two 
different DNAs, 2 µg of each plasmid was used for each well.  DNA was mixed with 0.25 M 
CaCl2 and 2x BBS buffer and incubated to develop fine precipitates. Empty vector, pcDNA3 
was used as negative control of transfection. 
200 µl of calcium-phosphate-DNA suspension was transferred into the medium above the cell 
monolayer in dropwise fashion. Cells were incubated at 37 °C / 5% CO2 for 24 hours. At the 
end of this incubation the medium and precipitates were removed by aspiration and 2 ml of 
fresh growth medium was added. 
 
3.3.5 Stimulation and lysis of the cells 
After 48 hours of transfection, medium was changed with serum free (starvation medium) 
medium and cells were incubated with this medium for 3 hours. At the end of this incubation 
cells were stimulated with 10 nM insulin to investigate insulin signal transduction or with 0.5 
µM 12-O-tetradecanoylphorbol-13-acetate (TPA) to activate novel and classical PKCs. 
After stimulation medium was removed and cells were washed with PBS. To perform lysis of 
the cells, 200 µl of lysis buffer 1 was added in each well of six well plates and  incubated at 
4°C for 5 min. To remove cell debris, cells were harvested and centrifuged for 5 min at 13000 
rpm and 4°C.The supernatant containing proteins was either processed for IP or mixed with  
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Laemmli (5X) and incubated at 95°C for 5 min. 40µg of protein was loaded on gel for   SDS-
PAGE. 
 
 
3.3.6 Cryopreservation of mammalian cells  
Mammalian cells are cryopreserved to avoid loss by contamination, to minimize genetic 
change in continuous cell lines, and to avoid aging and transformation in finite cell 
lines.  Before cryopreservation, cells were characterized and checked for contamination. The 
media used to freeze cells included 10% DMSO and 90% FCS. Cells growing in log phase 
were detached, centrifuged, the supernatant was removed and the cell pellet was suspended in 
freezing medium to a concentration of 5x106 to 1x 107cells. For cell suspension, aliquots were 
prepared into cryogenic storage vials. First cells were placed on ice and then stored at -80°C 
in liquid nitrogen. 
 
3.3.7 Statistical analysis 
After quantifying the data in Gelscan software, it was exported to excel. All data are 
expressed as means ± SEM. The one-tailed student’s unpaired test was used for comparison of 
mean values. Statistical significance was accepted at p < 0.05. 
 
3.4 Standard DNA-methods 
 
3.4.1 “Overlap” extension polymerase chain reaction (PCR) 
The PCR is a rapid procedure for the in vitro amplification of specific segments of DNA. A 
segment of DNA is amplified using specific two single-stranded oligonucleotides (primers). 
Furthermore, a DNA polymerase, deoxyribonucleoside triphosphate (dNTPs) and a buffer 
system are needed. Denaturation (melting the DNA to single strands), annealing (flanking of 
single stranded DNA by primers) and synthesis (amplification of complementary strands to 
produce double-stranded DNA) are the three components of PCR amplification cycle. Usually 
30 cycles are performed resulting in a 228-fold amplification of a discrete product. 
Site-directed mutagenesis can be used to change particular base pairs in a piece of DNA 
(163). In this work overlap extension PCR was used to introduce site-directed mutagenesis in 
the IRS-1 wild type gene. For a typical, one site directed mutagenesis reaction, for instance 
mutation of Ser-357 of IRS-1 to Ala357, two mutagenic primers were designed containing the 
mutation and completely complementary to each other (Table 2). Each primer was used in a 
separate reaction (separate tubes, same conditions) with an outer flanking primer pRK5'PCR 
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or IRS-1-318/1 designed to one end of the IRS-1. These two reactions were given names as 
reaction for fragment A and reaction for fragment B (Table 3).The PCR program was set as 
described in Table 4. Two halves of the IRS-1, “A” and “B” were generated in this manner in 
two separate reactions. PCR products were purified by using a PCR purification kit. In the 
next step both those fragments were put together (reaction for fragment C ,Table 5), where 
they anneal in the 25-30 bp region of complementarity and prime off each other, to give the 
IRS-1 product with the mutation, Ala357, in IRS-1. This PCR product was separated on 
agarose gel and its concentration was determined. Several other mutants of IRS-1 was 
generated in the same manner. 
 
Table 2. Primers used to generate different mutants of IRS-1by site directed mutagenesis. 
Plasmid  Mutagenic 
Upstream Primer 
Sequence  
pRK5-IRS-1 WT 
 
IRS-1-Ala357 
 
cc cac gcc cat cgg cat cga ggc gcc tcc agg ttg 
cac ccc cca ctc aac cac 
 
pRK5-IRS-1 WT 
 
IRS-1-Glu357 
 
cc cac gcc cat cgg cat cga ggc gag tcc agg ttg 
cac ccc cca ctc aac cac 
 
pRK5-IRS-1 WT 
 
IRS-1-Ala357/358 
 
cc cac gcc cat cgg cat cga ggc gcc gcc agg ttg 
cac ccc cca ctc aac cac, 
 
pRK5-IRS-1 WT 
 
IRS-1-Ala 358 
 
cc cac gcc cat cgg cat cga ggc agc gcc agg ttg 
cac ccc cca ctc aac cac 
 
pRK5-IRS-1 WT 
 
IRS-1-Glu357/ Ala 
358 
 
cc cac gcc cat cgg cat cga ggc gag gcc agg ttg 
cac ccc cca ctc aac cac 
 
pRK5-IRS-1 WT pRK5’ PCR flanking 
primer 
ttg cct ttc cca cag gtg 
pRK5-IRS-1 WT IRS-1 318 1 flanking 
primer 
gct gct gct gct gtt gct ctc gta ccc ggg gta aag t 
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Table 3. Reaction conditions for the amplification of fragment A and B of IRS-1 to generate IRS -1 
Ala-357 mutant. 
 
 
Table 4. PCR program for the amplification of fragment A and B of IRS-1 to generate IRS-1 Ala- 
357 mutant. 
 
 
Table 5. Reaction conditions for the amplification of fragment C of IRS-1 to generate IRS-1 Ala-
357 mutant. 
 
 
 
 
 
 
 
 
 
 
 
 
Content Reaction for 
Fragment A 
Reaction for  
Fragment B 
End concentration 
 Volume [µl]  
H2O 37.5 37.5  
10x Reaction buffer for Pwo polymerase (see 
2.1) 
2 2 1x 
pRK5'PCR primer 100 µM (see table 2) 1 - 2 µM 
IRS-1-318/1 primer 100 µM (see table 2) - 1 2 µM 
Ala 357 upstream primer 100 µM (see table 2) 
 
1 - 2 µM 
Ala 357 downstream primer 100 µM (see table 
2) 
- 1 2 µM 
Template DNA  100 ng/µL 2 2 4 ng/µL 
DNTPs 200 µM (see 2.1) 4 4 4 µM 
Pwo polymerase 1U/µL (see 2.1) 2.5 2.5 0.05 U/µL 
Segment Duration (min) Temperature cycles 
1 Denaturation 5 95°C 1x 
2 Annealing 1 55°C 
   Extension 6 72°C 
   Denaturation 1 95°C 
30x 
3 Annealing 1 55°C 
   Extension 5 72°C 
1x 
Reaction for IRS-1  
Ala 357 (Fragment C) 
End concentration Content 
Volume [µL]  
H
2
O  35.5   
10x Reaction buffer for Pwo polymerase  2  1x  
pRK5'PCR primer 100 µM  1  2 µM 
IRS-1-318/1 primer 100 µM  1  2 µM 
Fragment A ca. 100 ng/µL  2  4 ng/µL 
Fragment B ca. 100 ng/µL  2  4 ng/µL 
DNTPs 200 µM  4  4 µM  
Pwo polymerase 1 U/µL  2.5  0.05 U/µL 
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3.4.2 DNA electrophoresis in agarose gel and isolation from agarose gel 
The DNA from PCR reaction was diluted in DNA sample buffer and separated on horizontal 
agarose gels (1% agarose was prepared in 100 ml TAE buffer and 5 µl ethidium bromide (10 
mg/ml) was added). Gel was run in TAE buffer at 5 V/cm. The detection was carried out with 
a UV lamp. 
 
3.4.3 Isolation of DNA from agarose gel 
For the isolation of DNA from agarose gel, QIAquick ® Gel Extraction Kit from Qiagen was 
used. The bands were excised from the gel as closely as possible. Gel slice were dissolved in 
buffers as specified by the manufacturer. The elution was conducted in 30 µl dH2O. 
 
3.4.4 Determination of DNA concentration 
The DNA concentration was determined photometrically and calculated from the absorbance 
measured at 260 nm. Since a solution containing 50 µg per ml of double stranded DNA has an 
absorbance (optical density) of 1.0 at a wave length of 260 nm. Therefore, DNA concentration 
= absorbance (260 nm) x 50 µg/ml. DNA samples having a 260/280 ratio below 1.6 were 
discarded. 
 
3.4.5 Restriction digestion of mutated PCR product 
The PCR product containing the mutation at 357Ala of IRS-1 (fragment C) was excised from 
agarose gel and purified (3.4.3). The restriction digestion was carried out in order to separate 
the required insert containing 357 Ala mutations. 
Digestion of DNA was performed by incubating 1µl of each BamHI and XhoI restriction 
enzymes, with 3 µl of digestion buffer and 25 µl of PCR product of fragment C, at 37°C for 1 
hour. Restriction products were run on agarose gel and the 2500 bp band of interest was 
excised and purified. 
 
3.4.6 Ligation of the digested mutated product into expression vector 
The Purified restriction product was then ligated into the pRK5 IRS-1WT plasmid vector. 
Ligation reaction mixture consisted of 1 µl (10-50ng) of pRK5 IRS-1 WT (a BamHI and XhoI 
digested  fragment of the vector), 7 µl digested and mutated fragment of IRS-1 containing the 
mutation of Ala 357, 1 µl 10x of the ligation buffer and 1 µl ligase enzyme (1U/ µl). Reaction 
was set overnight at 16°C. 
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3.4.7 Transformation of ligation product in Ecoli 
The transformation of plasmid DNA into E. coli was made using heat shock method. 10 µl of 
the ligation product was mixed with 20 µl of KCM 5 x buffer (see 2.6) and 100 µl H2O was 
added and incubated on ice for 5 min. 100µl of competent E-coli XL1 Blue was added in the 
KCM mixture and incubated on ice for 30 min. At the end of this incubation, temperature 
shock was given at 42°C for exactly 2 min. 1 ml of LB media (see 2.7)was added in the 
mixture and incubated at 37°C for 30 min. Centrifugation was done at 6500 rpm for 2 min. 
The pellet was resuspended and plated on LB/Amp agar plates (see 2.7) and incubated at 37°C 
for overnight.  
 
3.4.8 Miniprep for isolation of plasmid DNA from Escherichia coli  
Positive clones from LB/Amp agar plates were incubated in 2 ml LB medium with ampicillin 
overnight at 37°C under shaking at 350 rpm. Plasmid DNA was isolated from E.coli, using 
Plasmid Mini Kit from Qiagen, according to manufacturer’s instructions. 
 
3.4.9 Sequencing 
 PCR was set to verify the mutated sequence of 357A in IRS-1. The sequencing of the 
manufactured constructs was made by the chain termination method of Sanger (164). The 
Premix (BigDye ® Terminator v.1.1 Cycle Sequencing Kit) contains the dNTPs (dATP, 
dCTP, dGTP, dTTP), fluorescence labeled ddNTPs, thermostable AmpliTaq ® DNA 
polymerase, a thermostable pyrophosphatase and magnesium chloride in Tris-buffer pH 9.0. 
For 10µl reaction, 300 ng of plasmid DNA as template, 4 µl of sequencing mix, 1 pM of 
318/1 Ala primer, 1x sequencing buffer and 3 µl of double distilled H2O was used. After 1 
min of initial denaturation, the PCR mix was incubated in the thermocycler for 30 of the 
following cycles: 10 sec denaturation at 96°C, 30 sec annealing at 50°C and 4 min elongation 
at 60°C.. The sequencing reaction products were purified by gel filtration and eluates were 
analyzed by capillary electrophoresis. The evaluation was done with the help of Abi Prism 
software "Sequencing analysis 3.7". The sequence comparison was performed on the Internet 
with BLAST, which is freely available at http://www.ncbi.nlm.nih.gov/blast. 
 
3.4.10 Isolation of plasmid DNA- maxiprep 
For the preparation of large amounts of plasmid DNA with great purity for the plasmid 
transfection into the mammalian cells, Maxi kit from Qiagen was used. A single bacterial 
colony from a selective agar plate was inoculated in 100 ml LB culture medium with 
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ampicillin. Culture was grown overnight on the shaker at 150 rpm / 37°C. The bacteria were 
then distributed into two 50 ml falcon tubes and centrifuged at 4000 rpm at 4°C for 10 min. 
The purification of DNA was performed according to manufacturer’s instructions. After 
drying the pellet, the DNA was dissolved in 100 µl H2O.The DNA concentration was 
determined as described in (3.4.4). The purity of the plasmid isolation was verified by 
restriction analysis (3.4.5) and subsequent agarose gel electrophoresis (3.4.2) or by 
sequencing (3.4.9). 
Some mutants of IRS-1 were also generated by Quick Change Site-Directed Mutagenesis kit,                               
Stratagene, following the manufacturer’s instructions. 
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4. RESULTS 
 
4.1 Characterization and specificity of phospho-Ser-357 Antibody  
  
4.1.1 Initial characterisation of antiserum raised against p-Ser-357 showed cross 
reactivity with adjacent Ser-358 
To identify novel Ser /Thr phosphorylation sites in IRS-1, in vitro phosphorylation assays 
were performed with the isolated N-terminal amino acid residues 2–304 and amino acid 
residues 265–522 of GST-IRS-1 protein fragments (146;165). Upon incubation of 
recombinant IRS-1 fragments with various PKC-isoforms, Ser-357 of rat IRS-1 (Ser-362 in 
human IRS-1) was identified as an in vitro PKC phosphorylation site (data not shown). Next, 
polyclonal phospho-site-specific antibodies were generated using a phosphopeptide sequence 
corresponding to the region of rat IRS-1 surrounding Ser-357 (Fig. 4). 
 
Fig. 4. Sequence alignment of the corresponding amino acid sequences around Ser-357 
and Ser-358 of IRS-1 proteins from different species. 
 Sequence alignment of the corresponding amino acid around Ser-357 for rat, mouse and 
human IRS-1 (amino acid numbers are indicated) is shown. Only the small region of rat IRS-1 
containing the sequence AHRHRGpSSRLHPPLNHSRSI (antigenic peptide can be seen as 
shaded box, * shows phosphorylated residue) IRS-1 351–367 was used for generation of 
polyclonal phospho-site-specific Ser-357 antibody. 
 
The antiserum was used to test the specificity of the phospho-site-specific-Ser-357antibody. 
Mouse skeletal muscle cell line C2C12 overexpressing IRS-1 WT were stimulated with 
insulin or phorbol ester 12-O-tetradecanoyl 13-phorbolacetate (TPA), a pharmacological 
activator of classical and novel PKC isoforms for 30 min (Fig. 5). Before stimulation, the 
341    PVSPSTNRTHAHRHRGSSRLHPPLNHSRSIPMPSSRCSPS 380Rat:
341    PVSPSTNRTHAHRHRGSSRLHPPLNHSRSIPMPSSRCSPS   380Mouse:
346    PVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPS  385 Human:
Ser357 Ser358
*
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antibody did not react with IRS-1, while insulin and TPA strongly stimulated phosphorylation 
of Ser-357, indicating that the antibody recognise phosphorylation of Ser-357. 
 
Fig. 5. Initial characterization of the antiserum raised against phospho-Ser-357. 
Antibody characterization for phospho-Ser-357 was performed in C2C12 cells transiently 
transfected with IRS-1 wild type (WT) (4 µg) and stimulated with TPA (0.5 µM) and insulin 
for 30 min. The blot was reprobed to show the expressed IRS-1 protein levels.  
 
To further verify that the antibody specifically recognises phosphorylation of Ser-357, an 
IRS-1Ala357 mutant was generated by PCR site-directed mutagenesis, to prevent 
phosphorylation at Ser-357. C2C12 cells were transiently transfected with either IRS-1 WT or 
IRS-1Ala357 mutant and stimulated with insulin or TPA for 30 min. Surprisingly,  
Fig. 6. Initial characterization of the antiserum raised against phospho-Ser-357. 
C2C12 cells were transiently transfected with either IRS-1 wild type (WT) or IRS-1 Ala357 
(4 µg each) and stimulated with insulin (10 nM) and TPA (0.5 µM) for 30 min. The blot was 
reprobed to show the expressed IRS-1 protein levels. 
 
IRS-1 WT
- ins   TPA
IRS-1 
pSer357  
IRS-1 WT IRS-1Ala357
IRS-1 
- ins       TPA
pSer357  
Con
- ins       TPA - ins    TPA
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phosphorylation signal detected by antiserum was comparable between IRS-1Ala357 and 
IRS-1WT expressing cells (Fig. 6), indicating an unspecific binding of the antibody, possibly 
a cross reactivity with the adjacent Ser-358.  
This was itself a novel phenomenon in the development of phospho-site specific antibodies 
for IRS-1. At this point we decided to eliminate cross reactivity of the antibody with Ser-358 
to elucidate single effect  of Ser-357 of IRS-1in insulin signaling , as prior studies has already 
described Ser-358 as a functional serine site of IRS-1 (166). 
 
4.1.2 Synthesis and purification of synthetic peptides 
In an attempt to immuno-purify antiserum and to determine specificity of purified- phospho-
site-specific-Ser-357 antibody by indirect ELISA it was decided to generate chemically 
synthesized phosphopeptides as antigens. The peptides were synthesized using standard 
Fmoc/tBu chemistry (Table 6). 
Table 6. Sequences of synthetic modified IRS-1 351-377 peptides. 
Crude peptides were purified using preparative reversed-phase high-performance liquid 
chromatography (RP-HPLC) Fig 7. The integrity of the peptides and phosphopeptides was 
verified by mass spectroscopy. Table 1 lists the sequences of the synthetic peptides. Each 
peptide was 20 amino acids long. The peptides were either unphosphorylated, contained 
single phosphate groups on Ser-357 or Ser-358, or phosphates on either serines or alanine at 
position 358. 
a) IRS-1 351-377;p357                                    AHRHRG+SRLHPPLNHSRSI
b) IRS-1 351-377;p357(Ala at 358 )                    AHRHRG+ARLHPPLNHSRSI
c) IRS-1 351-377; p357p358                           AHRHRG++RLHPPLNHSRSI
d) IRS-1 351-377;p358                                    AHRHRGS+RLHPPLNHSRSI
e) IRS-1 351-377;np357np358(Ala at 358) AHRHRGSARLHPPLNHSRSI
f) IRS-1 351-377;np357np358                       A HRHRGSSRLHPPLNHSRSI
Peptide Sequence
Plus(+) sign indicates phosphorylated amino acids
p = phosphorylated
np = non phosphorylated
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Fig. 7. RP-HPLC elution profile of synthetic modified IRS-1 351-377 peptides. 
Purified peptides were separated via analytical RP-HPLC using a C8 column (150 × 2 mm, 
Reprosil 100,) with the following solvent system: (A) 0.055% (v/v) trifluoroacetic acid in H2O, 
and (B) 0.05% (v/v) trifluoroacetic acid in ACN/H2O (4:1, (v/v)). The column was eluted with 
a 10-90% gradient of solvent B for 30 min. UV detection was carried out at 214 nm (a,b,c,d,e 
and f refers to the peptide sequences in Table 6). 
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4.1.3 Immuno-purification of antiserum and determination of specificity of 
purified phospho-site-specific-Ser-357 antibody by indirect ELISA 
 
Fig. 8.  Determination of specificity of polyclonal phospho-site-specific-Ser-357 antibody by 
indirect ELISA.. The purified polyclonal phospho-site-specific-Ser-357 antibody specifically 
recognizes phospho-Ser-357 of IRS-1 peptide and gives a negative reaction towards different 
related synthetic peptides. 5 µg of different synthetic peptides were coated on an ELISA plate. 
Phospho-site-specific-Ser-357 antiserum and purified phospho-site-specific-Ser-357 
Purified- pSer357
antibody 
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pSer357
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antibodies were used for the detection at dilutions of 1: 3000 and 1: 500 respectively. (B) 
Quantification of relative binding of each polyclonal antibody to phospho-Ser-357 of IRS-1 
protein-based synthetic peptides (listed in Table 5) using the PEPSCAN-ELISA method, 
values are mean +SEM, where n = 3. 
 
The generated phospho-site-specific-Ser-357 antibody was immuno-purified by multiple 
purification steps using non-phosphorylated Ser-357 and p-Ser-358 peptide. To determine and 
compare the specificity and cross-reactivity of the antiserum and purified-p-Ser-357 antibody, 
an indirect ELISA was performed using different non-phospho and phospho-synthetic 
peptides (Table 5). The results of the indirect ELISA (Fig. 8A) showed that the purified 
antibody binds specifically to the immunogenic phosphopeptide but not to the non-
phosphorylated form of the peptide or to other phosphopeptides (Fig. 8B), suggesting that the 
antibody specifically recognized phosphorylation of Ser-357 and showed complete negative 
reaction towards phosphorylation of adjacent Ser-358. 
 
4.1.4 Final determination of the specificity of purified phospho-site-specific-Ser-
357 antibody in living cells 
 In order to establish the specificity of the antibody against phosphorylation of Ser-357 at the 
entire IRS-1 protein, two more mutants of IRS-1 were generated: IRS-1 Ala358 to prevent 
phosphorylation at Ser-358 and a double mutant IRS-1Ala357/358 to prevent phosphorylation 
at both, Ser-357 and Ser-358, simultaneously. Baby hamster kidney cells stably expressing the 
human insulin receptor (BHKIR-cells) were transiently transfected with IRS-1 WT, IRS-1 
Ala357, IRS-1 Ala358 and IRS-1 Ala357/358 and stimulated with insulin or TPA for 30 min 
(Fig. 9A).  
 
The antiserum non-specifically recognized Ser-357 phosphorylation upon stimulation with  
TPA and insulin in the cells overexpressing IRS-1 Ala357 and IRS-1 Ala357/358 comparable 
to the cells overexpressing IRS-1WT and IRS-1 Ala358 (Fig. 6A, B).Whereas with the 
purified-p-Ser-357 antibody we detected almost no or a very low signal of phosphorylation 
was detected in IRS-1 Ala357 and IRS-1 Ala357/358-transfected cells, similar to the 
immunoblots obtained with control transfected cells (Fig. 9B). 
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Fig. 9. Specificity of phospho-Ser-357 antibodies on the entire IRS-1 protein analyzed in 
cultured cells. (A) Baby hamster kidney cells stably expressing the human insulin receptor 
(BHKIR-cells) were transfected with IRS-1 WT, IRS-1 Ala357, IRS-1 Ala358, and IRS-1 
Ala357/358 (4 µg each) and treated with insulin (10 nM, 30 min) or TPA (0.5 µM, 30 min). 
After stimulation, cells were lysed and analyzed by 7.5% SDS-PAGE and immunoblotted with 
phospho-site-specific-Ser-357 antiserum and purified-phosho-Ser-357 antibodies. The same 
blots were stripped and reprobed with a polyclonal IRS-1 antibody. Arrow indicates 
endogenous IRS-1 visible after long exposure.. Representative results from three independent 
experiments are shown. (B) Phosphorylation intensity of Ser-357 of IRS-1 was quantified 
based on scanning densitometry of immunoblots normalized for IRS-1 protein. (Mean +SEM, 
n = 3, *p < 0.05 IRS-1 Ala357 mutants vs. IRS-1 WT; # p < 0.05 IRS-1Ala357/358 mutant vs. 
IRS-1 WT). 
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The very low signal depends most likely on the endogenous IRS-1 in the transfected cells, 
which can be phosphorylated at Ser-357. These data clearly show that the immunopurified 
antibody recognizes also in vitro IRS-1 solely, when it is phosphorylated on Ser-357 without 
any cross-reactivity with the adjacent putative phosphorylation residue Ser-358. Similar 
results have been obtained using C2C12 skeletal muscle cells. 
 
4.1.5 Determination of specificity of purified phospho-site-specific-Ser-357 
antibody in living cells with dephosphorylated IRS-1 
To further confirm the specificity of the phospho-site-specific Ser-357 antibodies, C2C12 
cells were transfected with IRS-1 WT and stimulated with TPA. Immunoprecipitated IRS-1 
was incubated with λ-phosphatase at 37 °C for 30 min which led to a complete loss of the 
immunoreactivity of the antibody, indicating that dephosphorylated IRS-1 is not recognized 
(Fig. 10).  
 
 Fig. 10. Specificity of phospho-Ser-357-antibodies in cultured cells. 
C2C12 cells were transfected with IRS-1 WT (4 µg) and stimulated for 30 min with TPA 
(0.5µM). IRS-1 was immunoprecipitated with a polyclonal IRS-1 antibody and 
immunoprecipitates (IP) were incubated with buffer alone or with buffer and λ PPase (100 U) 
for 30 min at 30 °C and immunoblotted (IB) with the phospho-site-specific Ser-357 antibody. 
Addition of buffer without incubation at 30 °C served as another control. The same blot was 
stripped and reprobed with a polyclonal IRS-1 antibody. 
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4.1.6 Determination of specificity of phospho-Ser-357-antibodies in cultured cells 
with endogenous IRS-1 
Fig. 11. Specificity of phospho-Ser-357-antibodies in cultured cells with endogenous IRS-1. 
C2C12 cells were stimulated with insulin (10 nM, 30 min) or TPA (0.5 µM, 30 min). IRS-1 
was immunoprecipitated and immunoblotted with site-specific Ser-357 antibody and reprobed 
with a polyclonal IRS-1 antibody. 
 
In another set of experiments, we analyzed non-transfected C2C12 cells for phosphorylation 
of Ser-357. As shown in Fig. 11, phosphorylation of Ser-357 of endogenous IRS-1 was 
detected after stimulation with insulin or TPA. 
 
4.2 Phosphorylation of Ser-357 of IRS-1 in insulin signaling 
 
4.2.1 Insulin-stimulated phosphorylation of Ser-357 in C2C12 cells: Insulin dose 
kinetics    
In order to examine the effect of insulin on the phosphorylation of Ser-357, time- and dose 
response curves of insulin-stimulated phosphorylation of Ser-357 were studied. C2C12 cells 
overexpressing IRS-1 WT were treated with various insulin concentrations for 30 min. A dose 
dependent increase in Ser-357 phosphorylation after 30 min of insulin stimulation was 
observed (Fig. 12). 
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Fig. 12.  Insulin dose kinetics of Ser-357 phosporylation in muscle cells. 
C2C12 cells were transfected with IRS-1 wild type and treated with the indicated doses of 
insulin for 30 min and analyzed by immunoblotting with site-specific- Ser-357- antibody and 
reprobed with a polyclonal IRS-1 antibody. 
 
4.2.2 Insulin-stimulated phosphorylation of Ser-357 in C2C12 cells: Insulin time 
kinetics    
Fig. 13. Insulin-stimulated time kinetics of phosphorylation of Ser-357 in C2C12 cells.  
 The time course of insulin action on the phosphorylation of Ser-357 was investigated by 
stimulation of C2C12 cells transfected with IRS-1 wild type (IRS-1 WT) (4 µg) with 10 nM 
insulin for indicated time points. “Con” indicates cells transfected with empty vector. Cell 
lysates were analyzed by 7.5% SDS-PAGE. A representative immunoblot of three independent 
experiments with the site-specific Ser-357 antibody and reprobe of the same blot with the 
polyclonal IRS-1 antibody are shown. Densitometric quantification of the increase of Ser-357 
phosphorylation after insulin stimulation (mean +SEM, n = 3, *p < 0.05 vs. unstimulated 
cells.) 
IRS-1 WT
0          0        1        10     100     500 
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In order to examine the effect of insulin on the phosphorylation of Ser-357 observed in figure 
5, the time-response curve of insulin-stimulated phosphorylation of Ser-357 was studied. The 
phosphorylation kinetics of Ser-357 phosphorylation was performed using 10nM insulin for 
various time points. It was found that insulin induced significant phosphorylation of Ser-357 
after 5 minutes of stimulation with a maximum increase after 20 minutes. The site remained 
strongly phosphorylated until 60 minutes of insulin stimulation (Fig. 13A and B) implicating a 
potential role in an early and late phase of insulin signaling. 
 
4.2.3 PKC-δ mediates IRS-1 Ser-357 phosphorylation in C2C12 cells 
Ser-357 is located at putative phosphorylation motif for PKC (RXS/ SXR/ RXSXR) a family 
of Ser kinases whose novel and atypical isoforms (e.g. PKC-δ and PKC-ζ) have been 
described as potential IRS-1 kinases that modulate IRS-1 function (85;162;167). Since the 
novel isoform PKC-δ was able to phosphorylate Ser-357 in the in vitro phosphorylation assays 
(data not shown) and treatment with TPA as an activator of classical and novel PKCs resulted 
in the pronounced phosphorylation of Ser-357 (Fig. 5) we focused on the role of PKC-δ in 
Ser-357 phosphorylation in muscle cells. C2C12 cells transiently co-transfected with PKC–δ 
and IRS-1 WT and stimulated by insulin and TPA, showed significant increase in the 
phosphorylation of Ser-357 in comparison to cells transfected with IRS-1WT alone (Fig. 
14A). Phosphorylation of Ser-357 in unstimulated co-transfected cells was also observed, 
which might be due to basal activitiy of the cotransfected PKC-δ. Because TPA may have 
cellular targets other than PKC-δ, we co-transfected cells with IRS-1 and PKC-δ kinase 
negative mutant (KN). Phosphorylation of Ser-357 in unstimulated, insulin- and TPA-treated 
cells was significantly abrogated when PKC–δ-KN mutant was used (Fig. 14B). These 
findings suggest that the insulin and TPA-induced phosphorylation of Ser-357 required PKC-δ 
activity.  
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Fig. 14. PKC-δ-mediated IRS-1 Ser-357 phosphorylation in C2C12 cells. (A) C2C12 cells 
were transfected with IRS-1 wild type (WT), co-transfected with PKC-δ and IRS-1 WT or 
kinase-dead mutant of PKC-δ (PKC-δ KN) and IRS-1 WT (2 µg  each). Cells were stimulated 
with either 10 nM insulin or 0.5 µM TPA for 30 min. A representative immunoblot with the 
phospho-site-specific Ser-357 antibody and PKC–δ and reprobe of the same blot with the 
polyclonal IRS-1 antibody is shown. (B) Ser-357 phosphorylation intensity was quantified 
based on scanning densitometry of the immunoblots (means +SEM, n=3, * p < 0.05 PKC δ 
cotransfected cells vs. cells transfected with IRS-1 WT alone; # p < 0.05 PKC δ KN 
cotransfected cells vs. PKC δ cotransfected cells). 
 
4.2.4 Insulin induces the phosphorylation of Ser-357 in skeletal muscle of mice 
The rapid phosphorylation of Ser-357 during acute insulin stimulation might contribute to an 
early modulation of the insulin response. To determine whether insulin-stimulated 
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phosphorylation of IRS-1 on Ser-357 occurs in the whole organism, skeletal muscle from 
male mice was isolated after 5 min of insulin stimulation (4 IU/mouse, intravenously). 
Immunoblotting with the Ser (P) 357-specific antibody revealed a very rapid (within 5min) 
insulin-stimulated phosphorylation of Ser-357 in skeletal muscle from these mice (Fig. 15), 
similar to the results obtained in cell culture. The data indicate that insulin also stimulates the 
phosphorylation of IRS-1 Ser-357 in skeletal muscle tissue within minutes. 
 
Fig. 15. Insulin-stimulated phosphorylation of Ser-357 in vitro.  
Male CH3 mice were fasted overnight and subsequently intravenously injected with 4 IU of 
insulin into the inferior vena cava. Muscle samples were obtained after 5 min of insulin 
treatment. Shown are immunoblots of muscle tissue of 3 control and 3 insulin-treated mice. 
Ser357 phosphorylation intensity was quantified based on scanning densitometry of the 
immunoblots (means +SEM, n=7, * p < 0.05 insulin-treated mice vs. control). 
 
4.3 Functional role of phosphorylation of Ser-357 of IRS-1 in insulin-
stimulated signal transduction.  
 
4.3.1 The phosphorylation of Ser-357 of IRS-1 leads to reduced phosphorylation 
of Akt in skeletal muscle cells 
Next, the functional role of phosphorylation of Ser-357 in insulin signal transduction was 
investigated. The kinase PKB/AKT is an important insulin signaling molecule, shown to 
transduce the metabolic actions of insulin, including increases in transport and storage of 
glucose in muscle, and its activation is largely controlled by IRS-1 during insulin action 
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(47;168). Therefore, we studied the influence of Ser-357 of IRS-1 on the insulin-induced 
time-dependent phosphorylation of Akt. To examine a possible influence of the adjacent Ser-
358 residue, C2C12 cells were transiently transfected with IRS-1 WT, IRS-1 Ala357, and 
IRS-1 Ala358 and IRS-1 Ala357/358 and stimulated for various time points with 10 nM 
insulin (Fig. 16A).  
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Fig. 16. The phosphorylation of Ser-357 of IRS-1 leads to reduced phosphorylation of Akt 
in skeletal muscle cells. (A, B) C2C12 cells, transiently transfected with IRS-1 WT, IRS-1 
Ala357, IRS-1 Ala358, and IRS-1 Ala357/358 (A) or IRS-1 WT and IRS-1 Glu357(4 µg each) 
(B) were stimulated for 5, 10, and 60 min with 10 nM insulin. Cell lysates were analyzed with 
7.5% SDS-PAGE, and after Western blotting the phosphorylation of Ser-473 of Akt was 
investigated. The same blot was stripped and reprobed with an Akt protein antibody. The IRS-
1 amount was analyzed using a polyclonal IRS-1 antibody. (C) Phosphorylation intensity of 
Ser-473 of PKB/Akt was quantified based on scanning densitometry of immunoblots 
normalized for PKB/Akt protein. (Mean +SEM, n = 3,*p < 0.05 IRS-1 Ala mutants vs. IRS-1 
WT; # p < 0.05 IRS-1 Glu mutant vs. IRS-1 WT.) 
 
To mimick a permanent phosphorylation of Ser-357, cells also were transfected with IRS-1 
Glu357 (Fig. 12B). The insulin-dependent increase in Ser-473 phosphorylation of Akt was  
markedly increased in IRS-1 Ala357, IRS-1 Ala358 and IRS-1 Ala357/358 expressing cells 
after 10 and 60 min of insulin stimulation compared with cells expressing wild-type IRS-1   
(Fig. 12C). Of note, phosphorylation of Ser-357 and Ser-358 appeared to have similar 
negative effects on Akt phosphorylation with no additive effect when phosphorylation at both 
sites was prevented in the IRS-1 Ala357/358 mutant (Fig. 12C). 
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The possible negative role of Ser-357 phosphorylation in insulin action was further 
demonstrated in IRS-1 Glu357 expressing cells, which exhibited a significantly diminished 
Ser-473 phosphorylation of Akt after 10 and 60 min of insulin stimulation compared with 
wild-type expressing cells. Since we did not observe any difference of the two alanine mutants 
(Ala357 and Ala357/358) on insulin signal transduction we used in further experiments only 
IRS-1 Ala357/358. 
 
4.3.2 Insulin-stimulated phosphorylation of GSK-3α in skeletal muscle cells is 
modulated by Ser-357 phosphorylation of IRS-1. 
The sustained effect of Ser-357 phosphorylation on Akt suggests a physiological function of 
this site in downstream insulin signaling. Thus we asked whether the possible regulation of 
Akt activity was reflected by a modulation of its downstream effector GSK-3. C2C12 cells 
were transiently transfected with IRS-1 WT, IRS-1 Ala357/358 or IRS-1 Glu357 and 
stimulated for various time points with 10 nM insulin (Fig. 17A). The increase in Ser-21 
phosphorylation of GSK-3α was more pronounced in IRS-1 Ala357/358 expressing cells after 
10 and 60 min of insulin stimulation compared with cells expressing IRS-1 WT, while 
expression of IRS-1 Glu357 resulted in a clear decrease in this phosphorylation (Fig. 17B). 
Thus, the negative effect of Ser-357 phosphorylation on insulin signaling could also be 
demonstrated at the level of GSK-3. While both isoforms α and ß of GSK-3 were present in 
C2C12 cells (data not shown), we observed insulin-induced phosphorylation only at Ser21 of 
GSK-3α. These findings are in agreement with previous studies (169) which reported that the 
α-isoform of GSK-3 was more responsive to insulin as compared to GSK-3β and had a 
stronger association with parameters of insulin resistance. 
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Fig. 17. Insulin-stimulated phosphorylation of GSK-3α in skeletal muscle cells is 
modulated by Ser-357 phosphorylation of IRS-1. 
 (A) C2C12 cells were transfected with IRS-1 WT, IRS-1 Ala357/358 or IRS-1 Glu357. Cells 
were incubated with 10 nM insulin for the indicated times (0, 5, 10 and 60 min). Cell lysates 
were resolved by 7.5% SDS-PAGE and immunoblotted with Ser 21 of GSK-3α. The same blot 
was stripped and reprobed with a GSK-3α protein antibody. The IRS-1 amount was analyzed 
using a polyclonal IRS-1 antibody. (B) Phosphorylation intensity of Ser21 of GSK-3 was 
quantified based on scanning densitometry of immunoblots normalized for GSK-3α protein. 
(Mean +SEM, n = 3,* p < 0.05 IRS-1 Ala357/358 vs. IRS-1 WT; # p < 0.05 IRS-1 Glu357 vs. 
IRS-1 WT. 
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4.3.3 Effect of Ser-357 phosphorylation on insulin-stimulated Tyr 
phosphorylation of IRS-1.  
Fig.18. Effect of Ser-357 phosphorylation on insulin-stimulated Tyr phosphorylation of 
IRS-1.  
(A) C2C12 cells were transfected with IRS-1 WT, IRS-1 Ala357/358 or IRS-1 Glu357 (4 µg 
each). Cells were incubated with 10 nM insulin for the indicated times (0, 5, 10 and 60 min). 
IRS-1 was immunoprecipitated with a polyclonal IRS-1 antibody (IP) and immunoblotted (IB) 
with the phospho-tyrosine antibody. The same blot was stripped and reprobed with a 
polyclonal IRS-1 antibody. (B) Tyrosine phosphorylation of immunoprecipitated IRS-1 was 
quantified based on scanning densitometry of immunoblots normalized for IRS-1. (Mean ± SE, 
n = 3,*p < 0.05 IRS-1 Ala357/358 vs. IRS-1 WT; # p < 0.05 IRS-1 Glu357 vs. IRS-1 WT). 
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Among several mechanisms by which serine phosphorylation of IRS-1 modulates insulin 
signaling altered tyrosine phosphorylation of IRS-1 is a very obvious one (70) and it also been 
implicated in the negative effects of PKC-δ on insulin signal transduction (170). Therefore we 
investigate whether phosphorylation of Ser-357 of IRS-1 could reduce the proximal insulin 
signaling by preventing or mimicking phosphorylation at Ser-357 in C2C12 cells expressing 
IRS-1 WT, IRS-1 Ala357/358 or IRS-1 Glu357 (Fig. 18).  
Consistent with an inhibitory role of phosphorylation of Ser-357, insulin-stimulated tyrosine 
phosphorylation of IRS-1 was enhanced using IRS-1 Ala357/358 after 5 and 10 min of insulin 
stimulation, while it was reduced in IRS-1 Glu357 expressing cells after all time points of 
insulin stimulation studied (Fig. 18B). Together these experiments suggest that IRS-1 tyrosine 
phosphorylation was altered by Ser-357, and that phosphorylation of this residue can attenuate 
IRS-1 mediated insulin signaling cascade in muscle cells. 
 
4.3.4 Inhibition of the PKC-δ-induced downregulation of PKB/Akt 
phosphorylation by IRS-1 Ala357/358  
Activation of PKC isoforms leads to enhanced Ser/Thr phosphorylation of IRS-1 and thus is 
implicated in impaired insulin signal transduction (155). To illustrate this concept further, we 
focused on the inhibitory effect of PKC-δ in downstream insulin signaling i.e. on Akt 
phosphorylation and the potential role of Ser-357 hereby.  
TPA-pretreatment of C2C12 cells expressing PKC-δ and IRS-1 WT led to clear 
downregulation of the insulin-induced phosphorylation of Ser-473 of Akt, an effect prevented 
by co-transfection of PKC-δ KN indicating the inhibitory effect of PKC-δ on insulin action 
(Fig. 19A). Moreover, co-transfection of IRS-1 Ala357/358 could clearly reduce the 
inhibitory action of PKC-δ on insulin-induced Akt phosphorylation (Fig. 19B). Thus we 
conclude that phosphorylation of Ser-357, by PKC-δ at least partially mediates the adverse 
effects of PKC-δ on insulin signaling. 
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Fig. 19. PKC-δ and Ser-357 phosphorylation of IRS-1 mediated downregulation of insulin-
induced phosphorylation of Akt. (A) C2C12 cells were co-transfected with PKC δ and IRS-1 
WT, kinase-dead mutant of PKC δ (PKC δ KN) and IRS-1 WT or PKC δ and IRS-1 
WT357/358 Ala. Cells were stimulated with 10 nM insulin for 10 min (ins) or preincubated 
with 0.5 µM TPA for 20 min before insulin stimulation (TPA+ins). A representative 
immunoblot demonstrating the phosphorylation of Ser-473 of Akt and the reprobe of the same 
blot with an Akt protein antibody is shown. (B) Ser-473 phosphorylation intensity was 
quantified based on scanning densitometry of immunoblots ((means+SEM, n=3, # p < 0.05 
TPA + insulin vs. insulin alone in cells cotransfected with IRS-1 WT andPKC-δ, § p< 0.05 vs. 
IRS-1 WT and PKC-δ transfected cells.) 
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4.3.5 Influence of the phosphorylation of Ser-357 on the interaction of PKC-δ and 
IRS-1 
Fig. 20.  Influence of the Phosphorylation of Ser-357 on the Interaction of PKC-δ and IRS-
1. (A) C2C12 cells were transfected with IRS-1 WT, IRS-1 Glu357 or IRS-1 Ala357/358 (4 µg 
each). Cells were incubated with 10 nM insulin for the indicated times (0, 5, 10 and 60 min). 
PKC-δ was immunoprecipitated and co-precipitated IRS-1 was detected by immunoblotting. 
(B) Quantification based on scanning densitometry is shown as histogram. (Mean + SEM, n 
=4,*p < 0.05 IRS-1 Glu357 vs. IRS-1 WT; coprecipitated IRS-1 WT after 5 min of insulin 
stimulation was set as 1). 
 
Also it was studied whether the phosphorylation of Ser-357 could regulate the association of 
IRS-1 and PKC-δ. In IRS-1 WT-expressing cells an insulin-stimulated increase in the 
association of both proteins after 5 and 10 min of stimulation was observed (Fig. 20), similar 
to the results obtained in primary mouse skeletal muscle cells (171). The insulin-dependent 
recruitment of PKC-δ to IRS-1 appeared to be enhanced in IRS-1 Glu357 expressing cells 
after 5 min of insulin stimulation, while the mutation of Ser-357 to alanine showed similar 
effect as found for IRS-1 WT (Fig. 20).These data suggest that the phosphorylation of Ser-357 
IRS-1 WT Ala357/358Glu357
PKC-δ
IRS-1
B
0    5   10  60   0   5   10  60    0   5   10  60 min ins   
0
0.5
1.0
1.5
2.0
0    5   10  60   0   5   10  60  0   5   10  60    min ins   
IRS-1 WT Ala357/358Glu357
*
*
A
  65 
could be involved in the insulin-mediated regulation of the interaction of this serine kinase 
and IRS-1. 
 
4.3.6 The phosphorylation of Ser318 prevents the phosphorylation of Ser-357 of 
IRS-1 in the early phase of insulin action 
The important physiological balance between activation and termination of insulin action can 
be altered by Ser-/Thr-phosphorylation of insulin receptor substrate (IRS)-1. Phosphorylation 
of Ser318 enhances insulin signal transduction in the early phase of insulin action; while later-
on it is involved in the attenuation of the downstream insulin effects. We aimed to investigate 
the activation and interplay of Ser-318 and negative acting Ser-357. C2C12 cells were 
transiently transfected with IRS-1 WT or IRS-1 Ala318 and stimulated for various time points 
with 10 nM insulin (Fig. 21). The increase in Ser-357 phosphorylation was more pronounced 
in IRS-1 Ala318 expressing cells in basal condition and after 5 min of insulin stimulation 
compared with cells expressing IRS-1 WT. These results indicate that the phosphorylation of 
Ser-318 prevents in the early phase of insulin action the phosphorylation of Ser-357. 
Fig. 21. The phosphorylation of Ser318 prevents the phosphorylation of Ser-357 of IRS-1 in 
the early phase of insulin action. 
 C2C12 cells transfected with either IRS-1 wild type (WT) or IRS-1 Ala318 (4 µg of each) 
were stimulated for 5, 10 and 60 min with 10 nM insulin and the phosphorylation of Ser-357 
of IRS-1 was studied. The same blot was stripped and reprobed with a polyclonal IRS-1 
antibody. 
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Based on the very intense phosphorylation of Ser-357 by TPA, an activator of classical and 
novel PKCs (Fig.5), as well as findings of the phosphorylation of Ser-357 by the novel PKC, 
in C2C12 cells (Fig 10), and because members of all PKC classes can be activated by insulin 
Fig. 22. Effects of novel, classical and atypical PKC isoforms on phosphorylation of Ser-
357 in IRS-1. 
C2C12 cells were transfected with IRS-1 wild type (WT), co-transfected with PKC–δ and IRS-
1 WT, or PKC–θ and IRS-1 WT, or PKC–β1 and IRS-1 WT, or PKC– ζ and IRS-1 WT, or 
PKC–λ and IRS-1 WT. Cells were stimulated with either 10 nM insulin or 0.5 µM TPA for 30 
min. A representative immunoblot with the phospho-site-specific Ser-357 antibody and 
reprobe of the same blot with the polyclonal IRS-1 antibody is shown. 
 
(165;172-174), PKC isoforms other then PKC-δ were studied to see their effect on 
phosphorylation of Ser-357. C2C12 cells were transiently co-transfected with PKC–δ and 
IRS-1 WT, or PKC–θ and IRS-1 WT, or PKC–β1 and IRS-1 WT, or PKC– ζ and IRS-1 WT, 
or PKC–λ and IRS-1 WT   and stimulated by insulin and TPA. Cells expressing PKC–δ and 
IRS-1 WT   or PKC–θ and IRS-1 WT or PKC–β1 and IRS-1 WT showed significant increase 
in the phosphorylation of Ser-357 in comparison to cells transfected with PKC– ζ and IRS-1 
WT, or PKC–λ and IRS-1 WT   (Fig. 22). Taken together, these results suggest that the 
phosphorylation of Ser-357 in skeletal muscle cells is mediated by novel and classical PKCs, 
whereas atypical PKCs are not involved. 
 
4.8 Single effect of Ser 357, Ser 358 on insulin signal transduction  
 
4.8.1 Single effect of Ser-357 and Ser-358 on tyrosine phosphorylation of IRS-1 
In previous experiments, double Ala mutant (Ala 357/ Ala 358) was used to interpret the 
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however further substantiation. Therefore, single mutants Ala357 and Ala358 of IRS-1 were 
used along with double mutant Ala357/358 to observe their single effect on insulin signal 
transduction. 
 
Fig. 23. Single effect of Ser-357 and Ser-358 phosphorylation on insulin-stimulated Tyr 
phosphorylation of IRS-1. (A) C2C12 cells were transfected with IRS-1 WT, IRS-1 Ala357, 
IRS-1 Ala358 and IRS-1 Ala357/358(4 µg each). Cells were incubated with 10 nM insulin for 
the indicated times (0, 5, 10 and 60 min). IRS-1 was immunoprecipitated with a polyclonal 
IRS-1 antibody (IP) and immunoblotted (IB) with the phospho-tyrosine antibody. The same 
blot was stripped and reprobed with a polyclonal IRS-1 antibody. (B) Tyrosine 
phosphorylation of immunoprecipitated IRS-1 was quantified based on scanning densitometry 
of immunoblots normalized for IRS-1. (Mean ± SE, n = 3,* p < 0.05 IRS-1 Ala357 vs. IRS-1 
WT; # p < 0.05 IRS-1 Ala357/358 vs. IRS-1 WT). 
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C2C12 cells were transfected with each construct and insulin-stimulated tyrosine 
phosphorylation was determined by immunoblotting. Substitution of Ser-357 IRS-1 by 
Ala357 IRS-1 increased short and long term insulin stimulated tyrosine phosphorylation of 
IRS-1 (Fig 23A).Unlike Ala357 IRS-1, Ala358 IRS-1 displayed normal insulin-stimulated 
tyrosine phosphorylation in C2C12 cells, whereas the double mutant also displayed increased 
insulin stimulated tyrosine phosphorylation, supporting the idea that Ser-357 plays important 
regulatory role (Fig 23B). 
These experiments maintain the conclusion that phosphorylation of Ser 357 inhibit insulin 
stimulated tyrosine phosphorylation of IRS-1 while phosphorylation of Ser-358 apparently 
has no effect. 
 
4.8.2 Single effect of Ser-357 and Ser-358 on Thr 308 phosphorylation of PKB 
Fig. 24. The phosphorylation of Ser-357 of IRS-1 leads to reduced phosphorylation of Akt 
in skeletal muscle cells. (A) C2C12 cells, transiently transfected with IRS-1 WT, IRS-1 
Ala357, IRS-1 Ala358, and IRS-1 Ala357/358, (4 µg each) were stimulated for 5, 10, and 60 
min with 10 nM insulin. Cell lysates were analyzed with 7.5% SDS-PAGE, and after Western 
blotting the phosphorylation of Thr-308 of Akt was investigated. The same blot was stripped 
and reprobed with an Akt protein antibody. The IRS-1 amount was analyzed using a 
polyclonal IRS-1 antibody. (B) Phosphorylation intensity of Thr-308 of PKB/Akt was 
quantified based on scanning densitometry of immunoblots normalized for PKB/Akt protein. 
(Mean +SEM, n = 3,*p < 0.05 IRS-1 Ala mutants vs. IRS-1 WT.)  
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Previous results indicated a negative effect of Ser-358 on insulin-stimulated activation of PKB 
and since it was the only substantial effect of Ser-358 on insulin signaling molecules, 
therefore it needed further elucidation. Insulin-induced activation of AKT/PKB results from 
its phosphorylation at its two residues, Thr-308 and Ser-473 (8;175).Thus it was worthwhile 
to examine influence of Ser-357 and Ser-358 on PKB phosphorylation at Thr-308 as well. 
C2C12 cells were transiently transfected with IRS-1 WT, IRS-1 Ala357, and IRS-1 Ala358 
and IRS-1 Ala357/358 and stimulated for various time points with 10 nM insulin (Fig. 24A). 
The insulin-dependent increase in Thr-308 phosphorylation of Akt was markedly increased in 
IRS-1 Ala357 and IRS-1 Ala357/358 expressing cells after 5 and 10 min of insulin 
stimulation compared with cells expressing wild-type IRS-1 (Fig. 24B). Interestingly, cells 
expressing IRS-1 Ala358 showed comparable phosphorylation of Thr-308 as in IRS-1 WT 
leading to the conclusion that Ser-358 does not have a steady and pronounced effect on 
insulin-mediated activation of PKB. 
 
4.8.3 Single effect of Ser-357 and Ser-358 on GSK-3 phosphorylation  
 
Fig.25.  Single effect of Ser-357 and Ser-358 on GSK-3 phosphorylation of IRS-1. 
 (A) C2C12 cells were transfected with IRS-1 WT, IRS-1 Ala357/358 or IRS-1 Glu357. Cells 
were incubated with 10 nM insulin for the indicated times (0, 5, 10 and 60 min). Cell lysates 
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were resolved by 7.5% SDS-PAGE and immunoblotted with Ser 21 of GSK-3-3. The same blot 
was stripped and reprobed with a GSK-3α protein antibody. The IRS-1 amount was analyzed 
using a polyclonal IRS-1 antibody. (B) Phosphorylation intensity of Ser21 of GSK-3α was 
quantified based on scanning densitometry of immunoblots normalized for GSK-3α protein. 
(Mean +SEM, n = 3,* p < 0.05 IRS-1 Ala357 vs. IRS-1 WT; # p < 0.05 IRS-1 Ala357/358 vs. 
IRS-1 WT. 
The enhanced activation of PKB by Ser-357 phosphorylation was translated into higher   
phosphorylation of its downstream effectors. As shown in (Fig. 25A), GSK-3α underwent 
significantly higher phosphorylation in cells over expressing either IRS-1 Ala357 or IRS-1 
Ala357/358 as compared to cells expressing wild type IRS-1. On the contrary cells transfected 
with IRS-1 Ala358 showed insulin stimulated phosphorylation of GSK-3 to the similar extent 
as in the cells expressing IRS-1 WT. 
 
4.8.4 Phosphorylation of Ser-357 but not Ser-358 triggers deactivation of tyrosine 
phosphorylation of IRS-1, PKB and its downstream effectors ; relevance of 
phosphorylation of Ser-357 in human  
 
The main query which remained obscure and need further elucidation was, if Ser-358 is 
mutated to Ala, Ser-357 phosphorylation has a functional effect? This is important because in 
human IRS-1, Ser-558 is replaced by Ala-358. Therefore, in order to establish the functional 
effect of Ser-357 in human IRS-1, an IRS-1 mutant was constructed in which Ser-357 was 
constitutively phosphorylated, while phosphorylation at Ser-358 was permanently blocked.  
Using PCR site directed mutagenesis such mutant, IRS-1 357Glu/358Ala, was generated and 
further used to see its effect in insulin signal transduction. 
Phosphorylation of all three molecules of insulin signaling was reduced in the cells over- 
expressing either IRS-1 Glu357/Ala358 or IRS-1 Glu357 as compared to IRS-1WT 
expressing cells (Fig 26, 27, 28). These results clearly indicate that insulin stimulated 
Akt/GSK-3 phosphorylation and tyrosine phosphorylation of IRS-1 is regulated by Ser-357 
phosphorylation alone and does not effected by phosphorylation of adjacent residue Ser-358. 
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Fig. 26. Phosphorylation of Ser-357, but not Ser-358 triggers deactivation of PKB. (A) 
C2C12 cells, transiently transfected with IRS-1 WT, IRS-1 Glu-357Ala-358 and IRS-1 Glu-
357(4 µg each), were stimulated for 5, 10, and 60 min with 10 nM insulin. Cell lysates were 
analyzed with 7.5% SDS-PAGE, and after Western blotting the phosphorylation of Ser473 of 
Akt was investigated. The same blot was stripped and reprobed with an Akt protein antibody. 
The IRS-1 amount was analyzed using a polyclonal IRS-1 antibody. (B) Phosphorylation 
intensity of Ser473 of PKB/Akt was quantified based on scanning densitometry of 
immunoblots normalized for PKB/Akt protein. (Mean +SEM, n = 3,*p < 0.05 IRS-1 Glu-
357Ala-358 mutants vs. IRS-1 WT; # p < 0.05 IRS-1 Glu mutant vs. IRS-1 WT.) 
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Fig. 27. Phosphorylation of Ser-357 but not Ser-358 down regulate phosphorylation of 
GSK-3. (A) C2C12 cells, transiently transfected with IRS-1 WT, IRS-1 Glu-357Ala-358 and 
IRS-1 Glu-357(4 µg each), were stimulated for 5, 10, and 60 min with 10 nM insulin. Cell 
lysates were analyzed with 7.5% SDS-PAGE, and after Western blotting the phosphorylation 
of Ser-21 of GSK-3α was investigated. The same blot was stripped and reprobed with an 
GSK-3 protein antibody. The IRS-1 amount was analyzed using a polyclonal IRS-1 antibody. 
(C) Phosphorylation intensity of Ser-21 of GSK-3 was quantified based on scanning 
densitometry of immunoblots normalized for GSK-3 protein. (Mean +SEM, n = 3,*p < 0.05 
IRS-1 Glu-357Ala-358 mutants vs. IRS-1 WT; # p < 0.05 IRS-1 Glu mutant vs. IRS-1 WT.) 
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Fig. 28. Phosphorylation of Ser-357 but not Ser-358 down regulate tyrosine 
phosphorylation of IRS-1. (A) C2C12 cells were transfected IRS-1 WT, IRS-1 Glu-357Ala-
358 and IRS-1 Glu357. Cells were incubated with 10 nM insulin for the indicated times (0, 5, 
10 and 60 min). IRS-1 was immunoprecipitated with a polyclonal IRS-1 antibody (IP) and 
immunoblotted (IB) with the phospho-tyrosine antibody. The same blot was stripped and 
reprobed with a polyclonal IRS-1 antibody. (B) Tyrosine phosphorylation of 
immunoprecipitated IRS-1 was quantified based on scanning densitometry of immunoblots 
normalized for IRS-1. (Mean ± SE, n = 3,*p < 0.05 IRS-1 Glu357Ala358 vs. IRS-1 WT; # p < 
0.05 IRS-1 Glu357 vs. IRS-1 WT). 
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4.8.5 Insulin-induced phosphorylation of Ser-357 in human myotubes 
IRS-1 plays an essential role in peripheral insulin action and consequently in impaired insulin 
action (insulin resistance) in insulin sensitive tissues such as skeletal muscle. Therefore, 
investigation of the effects of physiologically relevant stimuli such as insulin were carried out 
on the phosphorylation of Ser-357 using human myotubes obtained from biopsies from 
quadriceps femoris. Insulin increased the phosphorylation of Ser-357 in human myotubes as 
compared to non-stimulated cells (Fig. 29). Additionally, since we observed in insulin or 
TPA-treated human myotubes enhanced phosphorylation of Ser357 of the endogenous human 
IRS-1 protein, which contain alanine instead of serine at position 358, it support the evidence 
that Ser-357 is functional site in human as well. 
 
Fig. 29.  Insulin-induced phosphorylation of Ser-357 in human myotubes. 
Human myotubes were treated with10, 100 nM insulin and 0.5 µM TPA for 30 min.IRS-1 was 
immunoprecipitated (IP) with a polyclonal IRS-1 antibody and Immunoblotted (IB) with the 
phosphorylation site-specific Ser-357 antibody.The same blot was stripped and reprobed with 
a polyclonal IRS-1 antibody. 
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5- DISCUSSION 
 The results of a number of studies have indicated that Ser/Thr phosphorylation can affect the 
ability of IRS-1 to transmit  insulin signal, most often in a negative fashion 
(83;101;103;111;165;170;176;177) ; therefore, the identification of IRS kinases and their 
target Ser phosphorylation sites is of physiological and pathological importance. Individual 
Ser-Thr phosphorylated sites of IRS-1 can make it a poor substrate for the IR kinase , 
resulting in the inhibition of downstream signaling molecules activation and insulin action 
(178). 
The family of protein kinase C (PKC) isoforms represents important modulators of signaling 
molecules which regulate among other cellular functions the metabolic and mitogenic 
properties of insulin. All classes of PKCs have been involved in this regulation, and the 
effects described so far covers the transduction of the positive effect of insulin on glucose 
uptake and insulin secretion by atypical and novel PKCs (179), the participation in the self-
induced attenuation of insulin action by atypical PKCs (173) , and the implication in lipid- 
and hyperglycemia-induced insulin resistance by classical and novel PKCs 
(142;177;180;181). These kinases are also activated by various inducers of insulin resistance, 
placing them at a point of convergence between physiological and pathological stimuli. 
 
 Data of the novel PKC isoform δ mirrored this positive and negative modulation of insulin 
signaling. PKC-δ is shown to be important for insulin stimulated glucose uptake (126), and it 
participates in the insulin-dependent activation of Akt (182). On the other hand, it has been 
shown that activation of PKC-δ by lipids and leptin is involved in the impairment of insulin 
signaling (165;183)  and in the induction of apoptosis of insulin-secreting cells (161). 
 
In addition, PKCs are involved in the subsequent downregulation of insulin signaling (155). 
PKCs may contribute to serine phosphorylation of IRS-1 in response to insulin, thereby 
involve in negative feed back of insulin signaling (170;184;185). Serine phosphorylation of 
IRS-1 appears to be a major mechanism for the adverse effects of PKC-δ on insulin action 
(155;165;170). While in vitro at least 18 PKC-δ-dependent phosphorylation sites in IRS-1 
have been identified (155), so far only two sites could be demonstrated to be phosphorylated 
in vitro and to be functionally active, these are Ser-24 and Ser-318 (165;170;186). None of 
these sites were shown to be phosphorylated upon insulin stimulation by PKC-δ, although 
insulin could activate PKC-δ and induce its association to IRS- 1 (187). 
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5.1 Characterization and specificity of phospho-Ser-357 antibody 
In the current study we could demonstrate Ser-357 of IRS-1 as a novel, genuine and PKC-δ-
dependent phosphorylation site in cells, which is phosphorylated upon insulin stimulation. 
This conclusion is based upon the fact that its phosphorylation after insulin treatment can be 
detected using phospho-site-specific antibodies that selectively recognize the phosphorylated 
form of Ser-357. 
 This site was first identified by an in vitro kinase assay and verified in cell culture systems 
using phospho-specific antibodies. Cross reactivity of the phospho-Ser-357 antibody with the 
adjacent serine site was eliminated by immuno purification. The specificity of the antibody, 
after immuno-purification, was first determined by ELISA and then demonstrated after 
phosphatase-treatment and using IRS-1 Ala357, IRS-1 Ala358 and IRS-1 Ala357/358 
mutants. It was necessary to include the Ala358 mutation since this amino acid adjacent to 
Ser-357 is also a serine residue in mouse and rat IRS-1 and has been reported as a putative 
phosphorylation site  by Liu,Y.F (83).  
 Finally, to determine whether our observations in the C2C12 cells were applicable to a more 
physiological system, we examined tissues from mice for the presence of the IRS-1 Ser-357 
phosphorylation. Extracts from muscle of insulin stimulated wild type mice exhibited 
phosphorylation of Ser-357 as compared to non stimulated mice. These results are therefore 
consistent with the hypothesis that Ser-357 is an insulin stimulated phosphorylation site of 
IRS-1. 
 
5.2 PKC-δ mediated IRS-1 Ser-357 phosphorylation  
In the present study we identified Ser-357 of IRS-1 as a PKC-δ mediated novel 
phosphorylation site. IRS-1 contains several PKC substrate motifs (RXS/SXR/RXSXR) and 
Ser-357 resides in one of these motifs (RGS/SSR/RGSSR). The results implicated PKC-δ as 
the responsible serine kinase for the phosphorylation of Ser-357 since it was the kinase used 
in the in vitro phosphorylation assays, it could be activated by phorbol ester and insulin. Here, 
we provide the evidence that our results are consistent with the hypothesis that Ser-357 of 
IRS-1 is phosphorylated by PKC- δ. Two lines of evidence support the notion that Ser-357 
serve as an in vitro substrate of PKC-δ. First, overexpression of PKC-δ enhanced 
phosphorylation of Ser-357 as compared to control cells. Second, PKC-δ KN (kinase 
negative) failed to mimic the stimulatory effects of its wild-type counterpart, when transiently 
overexpressed in muscle cells. That is, phosphorylation of Ser-357 of IRS-1 in cells required 
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intact kinase activity of PKC-δ. Since overexpression strongly enhanced the phosphorylation 
of Ser-357 also in unstimulated cells and expression of a kinase dead PKC-δ blocked the 
phosphorylation almost completely, this observation supports the hypothesis that PKC-δ is 
involved in phosphorylation of Ser-357. 
Our results also suggest the likelihood of involvement of classical PKCs and novel PKC 
isoforms other then PKC-δ in the phosphorylation of Ser-357 in skeletal muscle cells which 
support the hypothesis that Ser-357 is a PKC-dependent phosphorylation site. 
Direct phosphorylation of Ser-357 is possible by PKC-δ, but we cannot rule out the role of 
other kinases as the phosphorylation motif is not completely selective for PKCs. This site is 
found in the substrate motif of PKB/Akt, and calmodulin-dependent protein kinase II; thus 
these can be possible kinases involved in phosphorylation of Ser-357. Albeit, some studies 
report that PKC-δ  negatively regulates the insulin-induced JNK activation (188), but some 
studies indicate that novel PKCs can mediate serine phosphorylation of IRS-1 by activating 
MAP kinase and JNK in kidney and skeletal muscle cells (101;189) therefore, at present, we 
cannot completely rule out the possibility that PKC-δ can mediate indirect phosphorylation of 
Ser-357 by activating MAPKinase / JNK. While GSK-3 is highly improbable to mediate 
phosphorylation of Ser-357 because this site is not in the phosphorylation motif of GSK-3, 
besides, phosphorylation of GSK-3 is inhibited by Ser-357 phosphorylation and therefore it is 
unlikely that GSK3 can mediate phosphorylation of Ser-357. Hence, our study provides 
sufficient evidence that PKC-δ is at least partly responsible for cellular phosphorylation of 
Ser-357. 
 
5.3 Functional role of phosphorylation of Ser-357 of IRS-1 in insulin-
stimulated signal transduction.  
 
5.3.1 Influence of Ser-357 and Ser-358 phosphorylation on PKB/AKT  
To investigate the biological relevance of this phosphorylation site in insulin signaling, we 
compared effects of Ser-357 phosphorylation of IRS-1 on central molecules of insulin 
signaling. The key result of our study was that IRS-1 Ala357/358 can better propagate insulin 
signal as compared to IRS-1WT, which is manifested for instance by its ability to 
dramatically enhance PKB phosphorylation. This result indicates that Ser-357 and Ser-358 of 
IRS-1 are negative regulatory sites in insulin signal transduction. Additional findings support 
this conclusion, when Ser-357 was changed to Glu to mimic phosphorylation; insulin-
stimulated PKB phosphorylation was blocked. Overexpressed IRS-1Ala357/358 enhanced 
  78 
PKB phosphorylation to the similar extent as IRS-1 Ala357. This observation, further support 
the conclusion that mutation of both serine sites had no additive effect on insulin signal 
transduction. In order to further elucidate the single effect of these serine sites on insulin 
mediated PKB activity, regulation of phosphorylation of Thr-308 of PKB was tested with 
single mutants of IRS-1 (IRS-1 Ala357, IRS-1 Ala358 and IRS-1 Ala357/358), surprisingly it 
was observed that Ser-358 has no effect on Thr-308 phosphorylation while Ser-357 
maintained its consistent negative role in insulin signaling by down regulation of Thr-308. 
Since different kinases are involved in phosphorylation of PKB, Ser-473 being 
phosphorylated by mammalian target of rapamycin complex-2 (mTORC2) while   Thr-308 by 
PIP3-bound 3-phosphoinositide-dependent protein kinase-1 (PDK1) (8), it is likely that Ser-
357 and Ser-358 albeit being adjacent sites, exploit different pathways for the regulation of 
insulin signaling and  consequently contributed differently in down regulation of insulin 
signaling. 
 
5.3.2 Influence of Ser-357 phosphorylation on GSK-3  
Interestingly we were also able to translate this inhibitory effect of Ser-357 on the regulation 
of GSK3 activity, a downstream target of PKB. The double mutant IRS-1Ala 357/358 
displayed increase insulin stimulated Ser-21 phosphorylation of GSK-3. Conversely, 
substitution of Ser-357 with glutamic acid blunted phosphorylation of Ser-21 of GSK3-α 
during insulin stimulation indicating a constant and stable negative effect of Ser-357 in insulin 
signal transduction. 
 
5.3.3 Influence of Ser-357 phosphorylation on tyrosine phosphorylation of IRS-1 
The additional strength of our study is that our experimental data support the conclusion that 
phosphorylation of Ser-357 of IRS-1 inhibits insulin-stimulated tyrosine phosphorylation of 
IRS-1. Substitution of IRS-1WT with IRS-1Ala357/358 increased insulin-stimulated IRS-1 
tyrosine phosphorylation, whereas substitution of IRS-1Glu357 of IRS-1 decreased insulin-
stimulated IRS-1 tyrosine phosphorylation, supporting the conclusion that Ser-357 has an 
essential regulatory function in insulin signaling. Though the mechanism by which Ser-357 
blunted IRS-1 tyrosine phosphorylation of IRS-1 is not completely clear, but it might be 
possible that Ser-357 phosphorylation causes electrostatic blockade for access of IRS-1 to IR 
like other serine sites of IRS-1(44;179). Alternatively, Ser-357 phosphorylation might target 
IRS-1 to sub-cellular compartments inaccessible to the activated insulin receptor and thus 
inhibits subsequent IRS-1-mediated downstream insulin signaling. 
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5.4 Single effect of Ser 357 and Ser 358 on insulin signal transduction  
Ser-358  has  been reported to have both,  positive and negative effects on insulin signal 
cascade (177;190), but these studies were carried out  on  IRS-1 mutated at the multiple serine 
residues (IRS-1- Ala 265/302/325/336/358/407/408 mutant) and none of these studies focused 
on single effect of Ser-358 on insulin signaling.  Here a part of the studies was focused on 
IRS-1 mutated at only Ser-358. 
 
5.4.1 Single effect of Ser-357 and Ser-358 on tyrosine phosphorylation of IRS-1 
In order to confirm single effect of Ser-357 and Ser-358 on insulin signal transduction, single 
Ala mutants were used along with the double Ala to compare the effect of these serine 
residues on insulin signal transduction.In contrast to upregulation of tyrosine phosphorylation 
of IRS-1 by IRS-1 Ala357, IRS-1 Ala358 displayed normal insulin stimulated tyrosine 
phosphorylation, whereas the double Ala mutant also displayed increased insulin-stimulated 
tyrosine phosphorylation. These experiments support the conclusion that phosphorylation of 
Ser 357 inhibits insulin-stimulated proximal insulin signaling, while phosphorylation of Ser-
358 apparently had no effect on it. 
 
5.4.2 Single effect of Ser-357 and Ser-358 on GSK-3 phosphorylation of IRS-1 
To test the effect of Ser-358 on GSK-3 phosphorylation it was found that there was significant 
enhanced GSK-3 phosphorylation when Ala-357 IRS-1 was used, while Ala 358 IRS-1 
showed similar phosphorylation of GSK-3 as IRS-1WT. 
 
Over all, our data showed no effect of Ser-358 phosphorylation on insulin signaling, except at 
the level of Ser-473 phosphorylation of PKB. However, there is no effect of Ser-358 
phosphorylation on Thr-308 phosphorylation of PKB, tyrosine phosphorylation of IRS-1 and 
phosphorylation of GSK-3.  
Although in rodents both serine residues contribute to the Ser-473 phosphorylation of Akt, as 
shown by our previous experiments with cells overexpressing single mutants (Fig 16), 
nevertheless Ala 358 had no effect on Thr-308 phosphorylation of PKB, tyrosine 
phosphorylationof IRS-1 and on GSK-3 phosphorylation. On the other hand, Ser-357 
exhibited a consistent negative modulation of proximal and distal insulin signaling, as has 
been proven by using diverse loss of function and gain of function mutations at Ser-357 in 
IRS-1 molecule (IRS-1 Ala357, IRS-1 Ala358, IRS-1 Ala357/358, IRS-1 Glu357 and IRS-1 
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Glu357/Ala358). Therefore, we conclude that Ser-358 has a subordinate effect on overall 
insulin signal transduction as compared to Ser-357.  
Moreover Ser-357 has been conserved in rodents and human, while Ser-358 is absent in 
human. In the present study enough evidence was provided to support the conclusion that Ser-
357 but not Ser-358 has a conserved and putative function in insulin signal transduction. 
 
5.4.3 Phosphorylation of Ser-357,  but not Ser-358 triggers deactivation of 
tyrosine phosphorylation of IRS-1, PKB and its downstream effectors ; relevance 
of phosphorylation of Ser-357 in human  
Finally to determine whether our observations of Ser-357 phosphorylation and its impact on 
insulin signaling were applicable to human, a new mutant was generated, known as IRS-1 
357Glu/358Ala, because the human residue homologous to murine Ser-358 actually is 
alanine. Insulin-mediated phosphorylation of central molecules of insulin signaling was 
examined in C2C12 cells overexpressing IRS-1 WT or IRS-1 Glu357/Ala358 or IRS-1 Glu 
357. Tyrosine phosphorylation of IRS-1, PKB phosphorylation at Ser-473 and GSK-3 
phosphorylation at Ser-21 was reduced in the cells overexpressing either IRS-1 
357Glu/358Ala or IRS-1 Glu 357 as compared to IRS-1 WT expressing cells. These results 
clearly indicate that in human, insulin stimulated phosphorylation of these signaling 
molecules, at least in part, is regulated by Ser-357. In addition, it was also observed that in 
human mayotubes this site is phosphorylated in response to insulin and TPA. 
Therefore, Ser-357, but not Ser-358 is the primary phosphorylation site of IRS-1 both in 
rodents and human, which can modulate insulin signaling. 
 
5.4.4 The phosphorylation of Ser-318 prevents the phosphorylation of Ser-357 of 
IRS-1 in the early phase of insulin action 
To investigate the interplay of previously described phosphorylation site Ser-318 of IRS-1 
(110) and the phosphorylation of Ser-357 was of interest. It was observed that in the early 
phase of insulin action, the phosphorylated state of Ser-318 prevents the phosphorylation of 
Ser-357. Since phosphorylation of Ser-318 enhances insulin signal transduction in the early 
phase of insulin action; while later-on it is involved in the attenuation of the downstream 
insulin effects, while Ser-357 has a negative effect in insulin signal transduction, this can be 
the part of complex regulation of IRS-1 serine phosphorylation to keep a tight balance 
between activation and inhibition of insulin signal transduction. 
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5.4.5 Inhibition of the PKC-δ-induced downregulation of Akt phosphorylation by 
IRS-1 Ala357/358; potential mechanism behind downregulation of insulin 
signaling by PKC-δ  
Finally we addressed the hypothesis that insulin stimulated activation of PKC-δ may enhance 
serine phosphorylation of IRS-1 and attenuate the downstream effectors of insulin signaling. 
Prior studies have also attempted to explain the  mechanism employed by PKC-δ to down -
regulate insulin signaling, but these studies remained limited to the effect of PKC-δ on 
proximal insulin signaling/tyrosine phosphorylation of IRS-1 (155). We address the question 
about the effect of PKC-δ on distal insulin signaling.  The adverse effect of PKC-δ activation 
on insulin action was further demonstrated, when we induced the negative effect of PKC-δ by 
pre-treatment of IRS-1 WT- and PKC-δ- overexpressing cells with phorbol ester. We found 
that insulin stimulated PKB phosphorylation was blunted by PKC-δ and that PKC-δ is not 
sufficient to cause this effect independent of Ser-357 phosphorylation, supporting the idea that 
PKC-δ could mediate the physiological negative feed back of insulin signaling through 
phosphorylation of Ser-357. Thus, both, active PKC-δ and IRS-1 phosphorylated on serine 
357 are necessary for the observed adverse effects of phorbol ester-mediated PKC activation 
on insulin signaling. Taken together these results further strengthen the role of PKC-δ in 
attenuating insulin signaling via serine phosphorylation of IRS-1 and explain, at least in part, 
the inhibitory mechanism of PKC-δ in insulin signaling.  
The phosphorylation of Ser-357 did not result in the dissociation of PKC-δ and IRS-1, as it 
was e.g. reported for PKC-ζ and IRS-1 after phosphorylation of Ser318 (110), but even 
appeared to result in an enhanced recruitment. This could facilitate other serine 
phosphorylation events on IRS-1 e.g. the previously published PKC-δ-dependent sites Ser-24 
and Ser-318, or its receptor, leading to the described reduced tyrosine phosphorylation and 
attenuation of insulin signaling (170). Interestingly, the insulin-induced activation of PKC-δ 
has also been implicated in a positive modulation of insulin action. Overexpression of PKC-δ 
in mouse skeletal myotubes led to a very rapid increase in tyrosine phosphorylation of the IR 
without insulin stimulation, and overexpression of a dominant negative PKC-δ prevented the 
insulin-dependent tyrosine phosphorylation of the IR (125;187). Moreover, the insulin-
dependent activation of PKC-δ was shown to be important for a maximum stimulation of Akt 
in skeletal muscle cells (182). Thus, insulin alone might not be sufficient to induce the 
adverse effects of PKC-δ on insulin action. These effects of PKC-δ had been reported after 
pharmacological activation using phorbol ester (170), stimulation with leptin (165) or lipid 
infusion (183). Following this aspect, it must be noted that we observed an insulin-dependent 
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phosphorylation of Ser-357, but this effect was not as strong as the phosphorylation intensity 
after stimulation with phorbol ester. It could be speculated that in the pathophysiological 
situation of metabolic disturbance with hyperinsulinemia, hyperglycemia, and hyperlipidemia 
a more pronounced and sustained activation of PKC-δ occurs which then leads to a significant 
phosphorylation of Ser-357. This phosphorylation could then mediate the desensitizing effect 
on insulin action in combination with other phosphorylation events.  
 
Fig. 30. Schematic diagram outlining the role of Ser-357 of IRS-1 in insulin action in 
skeletal muscle cells. Arrow indicates change in phosphorylation. 
Insulin binding to IR results in recruitment of IRS-1 to the activated receptor and its tyrosine 
phosphorylation. Activated PKC-δ mediates Ser-357 phosphorylation of IRS-1. 
Phosphorylation of Ser-357 inhibits tyrosine phosphorylation of IRS-1 and appears to lead to 
the reduction of phosphorylation of PKB and GSK-3. This may eventually result in insulin 
resistance due to reduced glucose uptake and impaired glycogen synthesis. 
Ins Insulin  IRS-1  Insulin receptor substarte-1  
IR Insulin receptor  PKC  Protein kinase C 
PKB Protein kinase B  GSK-3 Glycogen-Synthase-Kinase 3 
P-Y Phosphorylated tyrosine  S Serine 
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Number of distinct models may explain the observed data (Fig. 30). The simplest 
interpretation is that activation of PKC phosphorylates IRS-1 at Ser-357 and possibly other 
serine residues, and this phosphorylation inhibits the subsequent ability of the IRS-1 to serve 
as a substrate for the IR tyrosine kinase and results in reducd tyrosine phosphorylation of IRS-
1. This event reduces IRS-1 ability to activate PKB and relay insulin signal further down 
stream i.e Phosphorylation of GSK-3. Deactivation of PKB and activation of GSK-3 may lead 
to reduce glucose uptake and reduced glycogen synthesis respectively which can be the basis 
of insulin resistance. Together, these data suggest that phosphorylation of Ser357 mediates at 
least in part the adverse effects of PKC-δ activation on insulin action. 
In summary, we could clearly show that the phosphorylation of Ser-357 is functional and 
resulted in impaired insulin-stimulated tyrosine phosphorylation of IRS-1, reduced activation 
of Akt and subsequently reduced phosphorylation of GSK-3. These data suggest that Ser-357 
is the primary site for the modulation of insulin signaling. Albeit, Ser-358 have an 
interchangeable and secondary function in mice and rats but in human only Ser-357 is 
functional. The substantial role of Ser-357 is underlined by the fact that in human IRS-1 Ser-
358 (position 363 in human IRS-1) is replaced by alanine and our data support the conclusion 
that this site is phosphorylated in human myotubes and still modulate insulin signaling when 
358 is Ala. In short, we identified Ser-357 as a new phosphorylation site in IRS-1 and showed 
that PKC-δ is the potential kinase involved in phosphorylation of Ser-357. Our results are 
consistent with the assumption that PKC-δ mediated phosphorylation of Ser-357 appears to be 
the part of physiological negative feedback inhibition of insulin signaling. In conclusion we 
demonstrated here a novel, functionally relevant serine residue of IRS-1, which could be 
involved upon PKC-δ-dependent phosphorylation in the attenuation of insulin signaling in the 
insulin resistant state. 
In future, the in vitro role of Ser-357 phosphorylation needs to be resolved using tissues from 
animals or humans with insulin resistance and to follow changes in the phosphorylation status 
of Ser-357 after therapeutic interventions. Additional work is needed to identify other PKC-δ 
-mediated important regulatory serine sites of IRS-1; this should help to provide a more 
complete understanding of the molecular basis of insulin resistance. 
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